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Abstract 
Background: Methicillin-resistant Staphylococcus aureus (MRSA) has become a major 
cause of hospital-acquired and community-acquired infections. This study aimed to 
investigate the epidemiological and genetic diversity of MRSA isolates in healthcare 
settings from 2015 to 2017 and to characterize the major MRSA clones and antibiogram 
trends in Palestine. 
Methodology: Samples and data were obtained from 112 individuals admitted to 
different hospitals of West Bank and Jerusalem. Antibiotic susceptibility patterns and 
staphylococcal chromosomal cassette mec (SCCmec) typing were determined. Further 
genes were typed by Staphylococcus aureus protein A (spa) typing and detection of panel 
of toxin genes, including: Panton-Valentine Leukocidin (PVL), ACME-arcA (a surrogate 
marker for arginine catabolic mobile element I), Toxic Shock Syndrome Toxin-1 (TSST-
1) and Exfoliative Toxin A (ETA).  
 
Results: All the 112 isolates of MRSA were susceptible to Vancomycin (100%). Also, 
almost all isolates were trimethoprim sulfamethoxazole (SXT) susceptible (81.3%). 
Resistance rates of the MRSA strains were as the following: all MRSA isolates were 
resistant to cefoxitin, penicillin G, amoxicillin/clavulanic acid, ceftriaxone and 
meropenem (100%), (63.4%) were resistant to erythromycin, (34.8%) were resistant to 
clindamycin, (38.3%) were resistant to ciprofloxacin, (23.2%) were resistant to 
gentamicin and (18.8%) were resistant to SXT. Of all the isolates, 32 isolates (28.6%) 
were multi-drug resistant (MDR), in which these isolates were resistant to at least three 
different non-β-lactam antibiotic groups. The majority of the isolates were identified as 
SCCmec type IV (86.6%), which is considered as a community associated “CA- MRSA”. 
Among 29 different found spa types, 5spa types: t386, t008, t044, t223 and t037 were 
predominant and represented 14 (12.5%), 12 (10.7%), 12 (10.7%), 11 (9.8%), 10 (8.9%) 
isolates, respectively. Thirty three isolates (29.5%) were positive for the PVL toxin gene, 
while the ACME-arcA toxin gene was present in 18.8 % of the isolates and 23.2% had 
the TSST-1 gene. All spa type t991 isolates were ETA positive (5.4%). The four major 
iv 
 
MRSA clones were: CC22 (15.2%), CC1 (13.4%), CC8 (13.4%) and CC80 (13.4%). In 
this study, USA-300 clone was found in 9 isolates (8.0%). This clone is considered as 
both resistant and highly virulent and can cause rapid tissue destructive infections in 
healthy young adults and children. It has caused great morbidity and mortality in the 
recent decades in USA.  
Conclusions: Our results provide important insights into the epidemiology of MRSA 
strains in Palestine with high carriage of different toxins. We report a diversity of MRSA 
strains in hospitals in Palestine, with frequent community acquired SCCmec type IV 
carriage. Knowledge of the dominant MRSA clones in our region with the antimicrobial 
susceptibility profile is necessary for selection of the appropriate empirical antimicrobial 
treatment for MRSA infections. 
Key words: MRSA, antibiogram, MDR, spa, SCCmec, PVL, ETA, TSST-1, arcA, USA-
300 clone. 
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ﻟﺒﻜﺘﻴﺮﻳﺎ ﺍﻟﻌﻨﻘﻮﺩﻳﺔ ﺍﻟﺬﻫﺒﻴﺔ ﺍﻟﻤﻘﺎﻭﻣﺔ  ﺍﻟﺘﻮﺻﻴﻒ ﺍﻟﺠﺰﻳﺌﻲ ﻭﺍﺧﺘﺒﺎﺭ ﺃﻧﻤﺎﻁ ﺍﻟﺤﺴﺎﺳﻴﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ
  ﻓﻠﺴﻄﻴﻦ. ﻟﻠﻤﻴﺜﻴﺴﻴﻠﻴﻦ ﻓﻲ
 
 ﻋﻄﺎﻑ ﺳﻠﻴﻤﺎﻥ ﺍﺑﺮﺍﻫﻴﻢ ﻫﺎﺩﻳﺔﺇﻋﺪﺍﺩ: 
 ﺩ. ﻛﻔﺎﻳﺔ ﻋﺰﻣﻲ ﺇﺷﺮﺍﻑ:
 ﺍﻟﻤﻠﺨﺺ:
 
ﻦ ( ﺳﺒﺒﺎً ﺭﺋﻴﺴﻴﺎً ﻟﻠﻌﺪﻭﻯ ﺍﻟﻤﻜﺘﺴﺒﺔ ﻣASRM) ﺍﻟﻌﻨﻘﻮﺩﻳﺔ ﺍﻟﺬﻫﺒﻴﺔ ﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻠﻤﻴﺜﻴﺴﻠﻴﻦ ﺃﺻﺒﺤﺖ ﺑﻜﺘﻴﺮﻳﺎ :ﺧﻠﻔﻴﺔ ﺍﻟﺪﺭﺍﺳﺔ
 ﻭﺍﻟﺠﻴﻨﻲ ﻟﻌﻴﻨﺎﺕ ﺑﻜﺘﻴﺮﻳﺎ ﺍﻟﻤﺎﺭﺳﺎ ﺍﻟﺘﻨﻮﻉ ﺍﻟﻮﺑﺎﺋﻲﻫﺪﻓﺖ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺇﻟﻰ ﺩﺭﺍﺳﺔ . ﺍﻟﻤﺴﺘﺸﻔﻴﺎﺕ ﻭﺑﻴﻦ ﺃﻓﺮﺍﺩ ﺍﻟﻤﺠﺘﻤﻊ
ﻭﺗﻮﺻﻴﻒ ﻣﺴﺘﻨﺴﺨﺎﺕ ﺑﻜﺘﻴﺮﻳﺎ ﺍﻟﻤﺎﺭﺳﺎ  7102ﺇﻟﻰ  5102ﻣﻦ ﻣﺮﺍﻛﺰ ﺍﻟﺮﻋﺎﻳﺔ ﺍﻟﺼﺤﻴﺔ ﻓﻲ ﺍﻟﻔﺘﺮﺓ ﻣﻦ ( ASRM)
 ﻭﻣﺪﻯ ﺍﺳﺘﺠﺎﺑﺘﻬﺎ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ ﻓﻲ ﻓﻠﺴﻄﻴﻦ. )senolc ASRM rojam(ﺍﻟﺮﺋﻴﺴﻴﺔ 
 
ﻣﺴﺘﺸﻔﻴﺎﺕ ﻣﺨﺘﻠﻔﺔ ﻓﻲ  ﻣﺼﺎﺑﻴﻦ ﺑﻌﺪﻭﻯ ﺍﻟﻤﺎﺭﺳﺎ ﻣﻦ ﻓﺮﺩﺍً  211ﺗﻢ ﺍﻟﺤﺼﻮﻝ ﻋﻠﻰ ﻋﻴﻨﺎﺕ ﻭﺑﻴﺎﻧﺎﺕ ﻣﻦ  :ﻣﻨﻬﺠﻴﺔ ﺍﻟﺒﺤﺚ
 )snrettap ytilibitpecsus citoibitna( ﺃﻧﻤﺎﻁ ﺍﻟﺤﺴﺎﺳﻴﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔﺍﻟﻀﻔﺔ ﺍﻟﻐﺮﺑﻴﺔ ﻭﺍﻟﻘﺪﺱ. ﺗﻢ ﺗﺤﺪﻳﺪ 
ﺗﺤﺪﻳﺪ ﺟﻴﻨﺎﺕ ﺃﺧﺮﻯ ﻣﺘﻌﻠﻘﺔ ﺑﺒﻜﺘﻴﺮﻳﺎ  (. ﺗﻢgnipyt cemCCS)ﻭﺃﻧﻮﺍﻉ ﺍﻟﺠﻴﻦ ﺍﻟﻤﺴﺆﻭﻝ ﻋﻦ ﻣﻘﺎﻭﻣﺔ ﺍﻟﻤﻴﺜﻴﺴﻠﻴﻦ 
ﺑﺎﻹﺿﺎﻓﺔ ﺇﻟﻰ ﺗﺤﺪﻳﺪ ﺟﻴﻨﺎﺕ )gnipyt )aps( A nietorp suerua succocolyhpatS( ﺍﻟﻤﺎﺭﺳﺎ، ﻣﻨﻬﺎ ﺑﺮﻭﺗﻴﻦ 
 enitnelaV-notnaPﺍﻟﺠﻴﻦ ﺍﻟﻤﺴﺆﻭﻝ ﻋﻦ ﺳﻢ، ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ: ﻣﺴﺆﻭﻟﺔ ﻋﻦ ﺗﻜﻮﻳﻦ  ﻓﻲ ﻣﻮﺍﺩ ﺳﺎﻣﺔ ﻓﻲ ﻫﺬﻩ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ
 nixot I tnemele elibom cilobataC eninigrAﻋﻦ ﺳﻢ ﻭﺍﻟﺠﻴﻦ ﺍﻟﻤﺴﺆﻭﻝ ،)LVP( nixot nidicokueL
 1-nixoT emordnyS kcohS cixoTﻟﻤﺴﺆﻭﻝ ﻋﻦ ﻣﺘﻼﺯﻣﺔ ﺍﻟﺼﺪﻣﺔ ﺍﻟﺴﻤﻴﺔ، ﻭﺍﻟﺠﻴﻦ ﺍ)Acra-EMCA(
  A nixoT evitailofoxE. ( )ATEﻭﺍﻟﺠﻴﻦ ﺍﻟﻤﺴﺆﻭﻝ ﻋﻦ ﺳﻢ  )1-TSST(
 
 001) nicymocnav ـﺍﻟ ﺗﺴﺘﺠﻴﺐ ﻟﻤﻀﺎﺩ (211)ﺃﻅﻬﺮﺕ ﻧﺘﺎﺋﺞ ﺍﻟﺒﺤﺚ ﺃﻥ ﺟﻤﻴﻊ ﻋﻴﻨﺎﺕ ﺍﻟﻤﺎﺭﺳﺎ ﺍﻟﻤﻌﺰﻭﻟﺔ : ﺍﻟﻨﺘﺎﺋﺞ
٪(. ﻛﺎﻧﺖ ﻣﻌﺪﻻﺕ ﻣﻘﺎﻭﻣﺔ ﺳﻼﻻﺕ  3.18)   TXSـﺗﺴﺘﺠﻴﺐ ﻟﻤﻀﺎﺩ ﺍﻟ ﻛﺎﻧﺖ ﻣﻌﺰﻭﻟﺔﺃﻏﻠﺐ ﺍﻟﻌﻴﻨﺎﺕ  ، ﺗﻘﺮﻳﺒﺎً ٪(. ﺃﻳﻀﺎً 
 ﻭ nitixofec ﻟﻜﻞ ﻣﻦ: ﻛﺎﻧﺖ ﻣﻘﺎﻭﻣﺔ ASRMﺍﻟﻤﻌﺰﻭﻟﺔ  ﻣﺎﺭﺳﺎﻴﻊ ﻋﻴﻨﺎﺕ ﻛﻤﺎ ﻳﻠﻲ: ﺟﻤ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ ASRM
، ﻓﻲ ﺣﻴﻦ ٪001()meneporem ﻭ enoxairtfec  ﻭ dica cinaluvalc/nillicixoma ﻭ  G nillicinep
 ﺍﻟـﻣﻀﺎﺩ  ٪( ﻛﺎﻧﺖ ﻣﻘﺎﻭﻣﺔ ﺇﻟﻰ8.43)ﻭ nicymhtyrE ـﻟﻤﻀﺎﺩ ﺍﻟ ﻛﺎﻧﺖ ﻣﻘﺎﻭﻣﺔﺍﻟﻤﻌﺰﻭﻟﺔ  ﻣﻦ ﺍﻟﻌﻴﻨﺎﺕ ٪(4.36)
  ﺍﻟـﻟﻤﻀﺎﺩ  ٪( ﻛﺎﻧﺖ ﻣﻘﺎﻭﻣﺔ2.32)ﻭ nicaxolforpic ـﻟﻤﻀﺎﺩ ﺍﻟ ٪( ﻛﺎﻧﺖ ﻣﻘﺎﻭﻣﺔ3.83)ﻭ nicymadnilc
 23 ﻫﻨﺎﻙ ، ﻛﺎﻧﺖﻋﻴﻨﺎﺕ ﺍﻟﻤﺎﺭﺳﺎ ﺍﻟﻤﻌﺰﻭﻟﺔ. ﻣﻦ ﺑﻴﻦ ﺟﻤﻴﻊ  TXSـﻤﻀﺎﺩ ﺍﻟ٪( ﻛﺎﻧﺖ ﻣﻘﺎﻭﻣﺔ ﻟـ8.81ﻭ ) nicimatneg
ﻣﻘﺎﻭﻣﺔ ﻟﻤﺎ ﻻ ﻳﻘﻞ ﻋﻦ ﺛﻼﺙ ﻣﺠﻤﻮﻋﺎﺕ  ﻴﻨﺎﺕ(، ﺣﻴﺚ ﻛﺎﻧﺖ ﻫﺬﻩ ﺍﻟﻌRDMﻸﺩﻭﻳﺔ )ﻟﻭﻣﺔ ﻤﻘﺎﻣﺘﻌﺪﺩﺓ ﺍﻟ٪( 6.82) ﻴﻨﺔﻋ
 ﻴﻨﺎﺕ ﺍﻟﻤﻌﺰﻭﻟﺔ. ﺗﻢ ﺗﺤﺪﻳﺪ ﻏﺎﻟﺒﻴﺔ ﺍﻟﻌ(scitoibitna matcal-β-non) ﻐﻴﺮ ﺍﻟﻼﻛﺘﺎﻣﻴﺔﺍﻟﻣﺨﺘﻠﻔﺔ ﻣﻦ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ 
 iv
 
 -AC" ﺎﻟﻌﺪﻭﻯ ﺍﻟﻤﻜﺘﺴﺒﺔ ﻣﻦ ﺍﻟﻤﺠﺘﻤﻊﻣﺮﺗﺒﻄًﺎ ﺑـﺮ ﻧﻮﻋﺎً (، ﻭﺍﻟﺬﻱ ﻳﻌﺘﺒ%6.68) VI cemCCSﻧﻮﻉ ﻣﻦ ﻋﻠﻰ ﺃﻧﻬﺎ 
 ".ASRM
ﻭ  440tﻭ  800tﻭ  683t:  sepyt apsﺍﻟـ ﺃﻧﻮﺍﻉ ﻣﻦ 5،  gnipyt aps ﺍﻟـﻣﻦ ﺧﻼﻝ  ﻭﺟﺪﺕ ﻧﻮًﻋﺎ ﻣﺨﺘﻠﻔًﺎ 92ﻴﻦ ﻣﻦ ﺑ
ﻣﻦ ٪(  9.8)  01٪( ﻭ 8.9) 11٪( ﻭ 7.01) 21٪( ﻭ 7.01) 21٪( ﻭ 5.21) 41ﻛﺎﻧﺖ ﺳﺎﺋﺪﺓ ﻭﺗﻤﺜﻞ  730tﻭ  322t
 ﺣﻴﻦ ﻛﺎﻥ ﺟﻴﻦ، ﻓﻲ eneg nixot LVP ُﻋﺰﻝ ﻣﻨﻬﺎ ٪(5.92)ﻋﻴﻨﺔ ﻣﺎﺭﺳﺎ  33ﺃﻳﻀﺎ،ُ ، ﻋﻠﻰ ﺍﻟﺘﻮﺍﻟﻲ. ﺍﻟﻌﻴﻨﺎﺕ ﺍﻟﻤﻌﺰﻭﻟﺔ
ﺠﻴﻦ ﻣﻦ ﺍﻟﻌﻴﻨﺎﺕ ﻛﺎﻥ ﻳﺤﻤﻞ ﺍﻟ ٪2.32ﻭ  ﻴﻨﺎﺕ ﺍﻟﻤﻌﺰﻭﻟﺔ٪ ﻣﻦ ﺍﻟﻌ8.81ﻓﻲ  ﻣﻮﺟﻮﺩ eneg nixot Acra-EMCA
  ﺗﺤﻤﻞﻛﺎﻧﺖ 199tﻣﻦ ﻧﻮﻉ  ﻴﻨﺎﺕ ﺍﻟﻤﻌﺰﻭﻟﺔ. ﺟﻤﻴﻊ ﺍﻟﻌeneg nixot 1-TSSTﺍﻟﻤﺴﺆﻭﻝ ﻋﻦ ﻣﺘﻼﺯﻣﺔ ﺍﻟﺼﺪﻣﺔ ﺍﻟﺴﻤﻴﺔ 
،  )%4.31( 1CC، )%2.51( 22CC:ﻛﺎﻧﺖﻟﻠﻤﺎﺭﺳﺎ )sCC( ﺍﻟﻤﺴﺘﻨﺴﺨﺎﺕ ﺍﻷﺭﺑﻌﺔ ﺍﻟﺮﺋﻴﺴﻴﺔ ٪(. 4.5) eneg ATE
 ﻋﻴﻨﺎﺕ 9ﻓﻲ  ASU-003ﺍﻟـ  enolcﺥ ﻋﻠﻰ ﺍﺳﺘﻨﺴﺎﺭ ، ﺗﻢ ﺍﻟﻌﺜﻮ. ﻓﻲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ)%4.31( 08CCﻭ  4.31() 8CC
 ﻟﺪﻯ ﻟﻸﻧﺴﺠﺔ ﻭﻣﺪﻣﺮﺓ ﺳﺮﻳﻌﺔﻳﻤﻜﻦ ﺃﻥ ﻳﺴﺒﺐ ﻋﺪﻭﻯ ﺣﻴﺚ ﻟﻠﻐﺎﻳﺔ  ﻭﻣﻤﺮﺽﻫﺬﺍ ﺍﻻﺳﺘﻨﺴﺎﺥ ﻣﻘﺎﻭﻡ ﺮ ﻭﻳﻌﺘﺒ٪(. 0.8)
ﻓﻲ ﻣﻌﺪﻻﺕ ﻛﺒﻴﺮﺓ ﻟﻠﻮﻓﺎﺓ ﻭﺍﻟﻮﻓﻴﺎﺕ ﻓﻲ ﺍﻟﻌﻘﻮﺩ ﺍﻷﺧﻴﺮﺓ ﻓﻲ ﺍﻟﻮﻻﻳﺎﺕ  ﺗﺴﺒﺐ ﻫﺬﺍ ﺍﻻﺳﺘﻨﺴﺎﺥ. ﻦ ﻭﺍﻷﻁﻔﺎﻝﺍﻟﺒﺎﻟﻐﻴﺍﻷﺻﺤﺎء 
 ﺍﻟﻤﺘﺤﺪﺓ ﺍﻷﻣﺮﻳﻜﻴﺔ.
 
 ﺍﻟﻤﺎﺭﺳﺎ ﺍﻟﻤﻮﺟﻮﺩﺓ ﻓﻲ ﻟﺴﻼﻻﺕ ﻮﺑﺎﺋﻲﺍﻟﺘﻨﻮﻉ ﺍﻟ ﻣﻬﻤﺔ ﺣﻮﻝ ﻳﺔﺭﺅ ﺗﻈﻬﺮ ﻧﺘﺎﺋﺞ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺍﻻﺳﺘﻨﺘﺎﺟﺎﺕ ﻭﺍﻟﺘﻮﺻﻴﺎﺕ:
 ﻓﻲﺳﻼﻻﺕ ﺑﻜﺘﻴﺮﻳﺎ ﺍﻟﻤﺎﺭﺳﺎ  ﻲ. ﻛﻤﺎ ﺗُﻘﺮ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻭﺟﻮﺩ ﺗﻨﻮﻉ ﻓﺟﻴﻨﺎﺕ ﻣﺨﺘﻠﻔﺔ ﻣﻦ ﺍﻟﺴﻤﻮﻡ ﻭﺟﻮﺩﻓﻠﺴﻄﻴﻦ ﻣﻊ 
ﺇﻥ ﻣﻌﺮﻓﺔ ﻣﺴﺘﻨﺴﺨﺎﺕ  ،ﺃﻳﻀﺎً  .VI cemCCS ﺍﻟﻤﻜﺘﺴﺐ ﻣﻦ ﺍﻟﻤﺠﺘﻤﻊ ﻨﻮﻉﺍﻟﻭﺍﻟﺘﻲ ﺗﺤﻤﻞ  ﺍﻟﻤﺴﺘﺸﻔﻴﺎﺕ ﻓﻲ ﻓﻠﺴﻄﻴﻦ
 ﻔﻌﺎﻝﺍﻟﻤﻨﺎﺳﺐ ﻭﺍﻟ ﺧﺘﻴﺎﺭﻻﺍ ﺟﺪﺍ ُﻣﻦ ﺃﺟﻞ ﺿﺮﻭﺭﻱ ﺃﻧﻤﺎﻁ ﺣﺴﺎﺳﻴﺘﻬﺎ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔﺍﻟﻤﻬﻴﻤﻨﺔ ﻓﻲ ﻣﻨﻄﻘﺘﻨﺎ ﻣﻊ  ﺍﻟﻤﺎﺭﺳﺎ
 ﻟﻌﻼﺝ ﻋﺪﻭﻯ ﺑﻜﺘﻴﺮﻳﺎ ﺍﻟﻌﻨﻘﻮﺩﻳﺔ ﺍﻟﺬﻫﺒﻴﺔ ﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻠﻤﻴﺜﻴﺴﻠﻴﻦ. 
 
، LVP، cemCCS، aps: ﻣﺎﺭﺳﺎ، ﺃﻧﻤﺎﻁ ﺍﻟﺤﺴﺎﺳﻴﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ، ﻣﺘﻌﺪﺩﺓ ﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻸﺩﻭﻳﺔ،ﺍﻟﻜﻠﻤﺎﺕ ﺍﻟﻤﻔﺘﺎﺣﻴﺔ
 . enolc 003-ASU، ATE ،1-TSST، Acra-EMCA
 
 
 
 
 
vii 
 
Table of Contents 
Dedication 
Declaration………………………………………………………………………………..i 
Acknowledgments………………………..………………………………………………ii 
Abstract………………………………………………………………………………….iii 
ﺺﺨﻠﻤﻟﺍ……………………………………………………………………………………..v         
Table of contents ...…………………………………………………..…………………vii 
List of Tables ………………………………………………………………...…………..x 
List of Figures………………………………………………………………………….xiii 
List of Abbreviations ……………………………………..……………………..…….xvi 
 
Chapter One: Introduction 
 
1.1  Background ………...…………………………..……………..…………..1 
1.2  Problem statement …………………………………………………..….…4 
1.3  Study justification ……………………………………………………...…4 
1.4  Study hypotheses ………...…………..……………………………..….....5 
1.5  Study goal ………………………………………………………………...5 
1.6  Study aim & objectives ..……………………………………………….…5 
1.7  Summary of thesis chapters………………………………………….……6 
 
Chapter Two: Literature review 
 
2.1  History of MRSA, epidemiology and target population ……….……...….7 
2.2 Common methodologies used for MRSA genotyping and toxin genes 
profiling ………………………………………………………………….11 
2.2.1  SCCmec typing ......….…...….…….……………………………...……..11 
2.2.2  Staphylococcus aureus protein A (spa) typing …....………….………....13 
2.2.3  Toxin gene profiling (PVL, TSST-1, ETA &ACME-arcA) ………...…..14 
2.2.3.1  Panton-Valentine Leukocidin (PVL) ……………………………………14 
viii 
 
2.2.3.2  Toxic Shock Syndrome Toxin-1 (TSST-1) ……………………..……….14 
2.2.3.3  Exfoliative Toxins (ETs) ..……………………………………………….15 
2.2.3.4  Arginine Catabolic Mobile Element (ACME) .………………………….15 
2.3  Global epidemic status of MRSA .………………………………………16 
 
Chapter Three: Methodology 
 
3.1  Bacterial strains and data collection……………………………..………17 
3.2  Bacterial culture and identification of MRSA strains …………………..17 
3.3  Antimicrobial susceptibility testing ……………………………………..18 
3.4   Freezing of MRSA isolates ………………………….…………………..19 
3.5  DNA Extraction and Quantification …………………………………….19 
3.6  Molecular characterization of the strains: Typing of isolates …...………22  
3.6.1  PCR identification of SCCmec types ……………………………………22 
3.6.2  PCR identification of spa types ….……………….……………..………22 
3.6.3  Sequencing of spa amplicons ………………………...………………….25 
3.6.4  Phylogenetic Analysis ……..…………………………………………….26 
3.6.5 PCR identification of staphylococcal genes for virulence factors and 
toxins …………………………………………………………………….27 
3.7  PCR Conditions ………….…………...…………………………………28 
3.8  Agarose Gel Electrophoresis …………………………………………….29 
3.9  Ethical Considerations …….…………………………………………….30 
3.10  Statistical Analysis ……..……………...………………………………...30 
 
Chapter four: Results 
 
4.1  Bacterial isolates and study populations …………….…………………..31 
4.2  Detection of MRSA by cefoxitin disk diffusion test  and mecA gene .…39 
4.3  Antimicrobial susceptibility patterns ……………………………………41 
4.4  Molecular characterization and typing of isolates …………..……….….43 
4.4.1  SCCmec typing …………………………………………………….……43 
ix 
 
4.4.2  Spa typing ….……………………………………………………………45 
4.4.3  Phylogenetic analyses of the spa gene ……………..……………………52 
4.4.4  Toxin gene profiling …………………………………………………….55 
4.4.4.1  Detection of PVL toxin gene …...……………………………………….55 
4.4.4.2  Detection of ACME-arcA toxin gene …...………………………………58 
4.4.4.3  Detection of TSST-1 gene …………..…………………………………...60 
4.4.4.4  Detection of ETA gene ………….………………………………………62 
4.5   Major MRSA clone in this study ..………………………………………63 
4.6   Other MRSA clone ………………………………………………..…….72 
 
Chapter 5: Discussion, Conclusions, Limitations and Recommendations 
 
5.1   Discussion …….…………………………………………………………76 
5.2   Conclusions ……………………….……………………………………..85 
5.3  Limitations and Strengths ……………………………...………………..85 
5.4  Recommendation ……….……………………………………………….86 
5.5   Future plan ………………..……………………………………………..86 
 
Chapter five: References ………………………………………………………...…….87 
Chapter six: Appendices …………………………….………………………....…….101 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Tables 
 
No.      Table Title                                 Page No. 
 
Table 3.1 Primer sequences and target amplicons used for the SCCmec typing in this 
study .............. .................................................................................................................... 23 
 
Table 3.2 Multiplex reaction conditions for SCCmec typing using either Syntezza or 
Thermo Scientific PCR Master Mix .................................................................................24 
 
Table 3.3 Gel band patterns and lengths for the multiplex SCCmec typing used in 
this study . .......................................................................................................................... 25 
 
Table 3.4 All Target genes and primers used in this study. ....................................... 28 
 
Table 3.5 Thermal cycler programs used for the amplification of the targeted genes 
and toxins in this study. ..................................................................................................... 29 
 
Table 4.1 Relationship between gender and age groups of MRSA isolates in this 
study...................................................................................................................................37 
 
Table 4.2 Patient types of the study population……………………………….……37 
 
Table 4.3  Distribution of the MRSA isolates among the different hospital wards ..38 
 
Table 4.4 All the spa-types found in this study by spa typing …………………….47 
Table 4.5 The MLST-CCs and the related spa types found in this study by the BURP  
……………………………………………………………………………50 
 
 
xi 
 
Table 4.6 PVL positive isolates and their SCCmec types as found in this study…...56 
 
Table 4.7 The distribution of the PVL positive and negative isolates among their spa 
types and CCs as found in this study …………………………...……………………….57 
 
Table 4.8 The distribution of the ACME-arcA positive and negative isolates among 
their spa types and CCs as found in this study ………………………………………….60 
 
Table 4.9 The distribution of the TSST-1 positive and negative isolates among their 
spa types and CCs as found in this study ……………..…………………………………62 
 
Table 4.10 Genotypic and phenotypic characteristics of spa type t386 as found in this 
study ……………………………………………………………………………………..64 
 
Table 4.11 Genotypic and phenotypic characteristics of spa type t008 as found in this 
study ……..………………………………………………………………………………66 
 
Table 4.12 Genotypic and phenotypic characteristics of spa type t044 as found in this 
study ..……………………………………………………………………………………67 
 
Table 4.13 Genotypic and phenotypic characteristics of spa type t044 as found in this 
study …………………………………………………………………………………….69 
 
Table 4.14 Genotypic and phenotypic characteristics of spa type t037 as found in this 
study ……………………………………………………………………………………..70 
 
Table 4.15 Genotypic and phenotypic characteristics of spa type t021 as found in this 
study …………………..…………………………………………………………………71 
xii 
 
Table 4.16 Genotypic and phenotypic characteristics of spa type t991 as found in this 
study ……………………………………………………………………………..………72 
 
Table 4.17 Genotypic and phenotypic characteristics of the other spa types as found 
in this study …………………………………………………….………………….…….73 
 
Table 4.18 The molecular and antibiogram items, the phenotypic and genotypic 
characteristics of all MRSA isolates included in this study ….………………………….74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Figures 
 
No.     Figure Title                            Page No. 
 
Figure 2.1 Genetic organization of the mecA gene complex in the SCCmec sequenced 
strains (N315) isolated in Japan in 1981 ……...……...…………………………..……….9 
 
Figure 2.2 A timeline of the four waves of antibiotic resistance in S. aureus ...........11 
 
Figure 3.1: A: A table taken as a snapshot from the (Nanodrop 1000 spectrophotometer) 
for some representative randomly selected extracted samples that were used as template 
DNA for the genotyping profile. B: A graph of a representative extracted DNA sample as 
examined on the Nanodrop 1000 spectrophotometer ……………………..…………….22 
 
 
Figure 4.1 Number of isolates and their distribution among hospitals as collected in 
this study ………………...………………………………………………………………32 
 
Figure 4.2 :  A map of Jerusalem (Al-Quds) and the West Bank showing the 
distribution of MRSA isolates among hospitals which are included in this study 
(Sampling area) ………………………………………………...………………..………33 
 
Figure 4.3  Number of patients and their place of residence as collected in this study 
……………………………………………………………………………34 
 
Figure 4.4 MRSA distribution according to gender …………….……….………….35 
 
Figure 4.5 Distribution of age groups of patients that isolates were collected from 
during this study …………………………………………………………………………36 
 
Figure 4.6 The distribution of the different sources of MRSA isolates that have been 
involved in this study ……………………………………………………………………39 
 
xiv 
 
Figure 4.7 The disk diffusion method for the detection of MRSA. Two representative 
MH plates (A & B) showing the resistance pattern to cefoxitin (red arrows) by MRSA 
isolates ……...……………………………………………………………………………40 
 
Figure 4.8 A representative agarose gel electrophoresis for the mecA gene detection 
in MRSA ………………………………………………………………………………...41 
 
Figure 4.9      Antimicrobial resistance rates among all MRSA isolates in this study….42 
 
Figure 4.10  Distribution of the MDR isolates according to source …………….……42 
 
Figure 4.11 A representative agarose gel electrophoresis for the multiplex SCCmec 
typing for some representative isolates involved in this study ………………………….43 
 
Figure 4.12  The SCCmec type V that was detected in only one isolate in this study .44 
 
Figure 4.13 The distribution of the SCCmec types as found in this study ……….…..45 
 
Figure 4.14 A representative agarose gel electrophoresis for the spa typing PCR with 
the different band sizes for some representative samples involved in this study….…….46 
 
Figure 4.15  All the MLST-CCs found in this study by the BURP analysis ………...48 
Figure 4.16 A Scheme  represents the tree phylogram and the interrelationship 
between the sequencing derived from the spa sequencing and their correlation repeat 
sequences found through the spa typing ……………………………….………………..54 
Figure 4.17  A representative agarose gel electrophoresis for the PVL toxin gene ….55 
Figure 4.18 The distribution of the PVL positive isolates among their CCs ……...…58 
 
Figure 4.19 A representative agarose gel electrophoresis for the ACME-arcA toxin 
gene ……………………………………………………………………………...………58 
xv 
 
 
Figure 4.20 A representative agarose gel electrophoresis for TSST-1 gene …………61 
 
Figure 4.21 A representative agarose gel electrophoresis for the ETA gene ………...64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
List of abbreviations 
Abbreviation Full Term 
 
S. aureus  Staphylococcus aureus 
SSTIs    Skin and soft tissue infections 
MRSA    Methicillin Resistant Staphylococcus aureus 
PBP       Penicillin-binding protein 
CA-MRSA        Community acquired Methicillin Resistant Staphylococcus aureus 
HA-MRSA                 Hospitals acquired Methicillin Resistant Staphylococcus aureus 
PVL       Panton-Valentine Leukocidin 
SCCmec  Staphylococcal Cassette Chromosome mec 
ccrA and B               Cassette chromosome recombinases A and B 
SXT                          Trimethoprim-sulfamethoxazole 
VISA   Vancomycin Intermediate Staphylococcus aureus 
VRSA                       Vancomycin-resistant Staphylococcus aureus 
PCR                        Polymerase chain reaction 
Spa   Staphylococcus aureus protein A 
Ig   Immunoglobulin 
bp   Base pair 
SSRs   Short sequence repeats 
TSST-1                  Toxic shock syndrome toxin-1 
ETs                      Exfoliative Toxins 
ACME                Arginine Catabolic Mobile Element 
SSSS                  Staphylococcal scalded skin syndrome 
MLST                 Multi -locus sequence typing 
BURP                 Based Upon Repeat Pattern 
CCs                     Clonal complexes 
TAE                             Tris Acetate EDTA 
EDTA   Ethylenediaminetetraacetic acid  
UV                              Ultra-violet light 
xvii 
 
CSF               Cerebrospinal fluid 
CVP                   Central venous pressure 
CMSA                  Coagulase Mannitol Salt Agar 
BHI                      Brain heart infusion 
FOX   Cefoxitin Antibiotic 
CLSI                Clinical Laboratory Standards Institute 
MOH                Ministry of Health 
SPSS               Statistical Package for Social Sciences 
MH                Mueller-Hinton 
ICU                          Intensive Care Unit 
NT   Non-typeable 
Pen G   Penicillin G 
AMC   Amoxicillin/Clavulanic acid 
CRO   Ceftriaxone 
MEM   Meropenem 
E   Erythromycin 
C    Clindamycin 
CIP   Ciprofloxacin 
CN   Gentamicin 
V   Vancomycin 
 
 
 
 
 
 
 
 
 
1 
 
 
Chapter One:  
 
Introduction 
 
1.1 Background: 
 
Staphylococcus aureus (S. aureus) is an important bacterial pathogen in both community 
and healthcare-related settings in different parts of the world. It is one of the major 
human pathogens  that can cause a broad variety of human diseases ranging from mild 
skin and soft tissue infections (SSTIs) to sever life-threatening invasive infections; such 
as: endocarditis, osteomyelitis, necrotizing pneumonia, bacteremia, septicemia, septic 
arthritis, meningitis, food poisoning and toxic shock syndrome (Bazzoun, Harastani, 
Shehabi, & Tokajian, 2014; Harastani & Tokajian, 2014; Kobayashi, Malachowa, & 
DeLeo, 2015; Serray et al., 2016; Tong, Davis, Eichenberger, Holland, & Fowler, 2015). 
S. aureus is gram-positive cocci, arranged in clusters and described as “grape like”. It is 
catalase positive, coagulase positive, mostly beta hemolytic on blood agar medium and a 
salt tolerant organism (tolerates up to 10% salt concentration). It can grow at a wide 
range of temperatures between 18 °C and 40 °C, (optimal 35 °C), aerobically or 
anaerobically (facultative). This bacteria have many potential toxins and virulence factors 
that can easily evade the immune system and disrupt phagocytosis, such as the capsule 
and protein A which is considered as an immunoglobulin binding protein (Foster, 1996; 
Taylor & Unakal, 2018). 
S. aureus is a pervasive member of the human microbiological flora with up to 20-30% of 
humans that are persistently asymptomatically colonized with S. aureus on their skin or 
mucous membranes. However, 50-60% are occasionally colonized in the anterior nares 
(Frank et al., 2010; Gorwitz et al., 2008; J. A. Kluytmans & Wertheim, 2005; Otto, 2013; 
Wertheim et al., 2005; Williams, 1963). Moreover, a higher rate was reported for S. 
aureus as a human colonizer in approximately 30-50% of individuals, elsewhere (Noble, 
Valkenburg, & Wolters, 1967; Sowash & Uhlemann, 2014). 
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When S. aureus invades the skin or the mucosal surfaces, it can cause severe diseases and 
invasive infections. However, S. aureus carriage has been seen as a significant risk factor 
for S. aureus infections, in both healthy and chronically ill patients, especially the 
immunocompromized and hospitalized patients (Kooistra-Smid, Nieuwenhuis, van 
Belkum, & Verbrugh, 2009; Laupland, Ross, & Gregson, 2008). However, S. aureus 
pathogenesis and severity of the infections are usually related to different factors; such 
as: host colonization, immune system, infection site, acquisition of novel genetic 
elements and virulence factors and toxins carried by S. aureus (Krakauer & Stiles, 2013; 
Krishna & Miller, 2012; Liu, 2009). So, the carriage of S. aureus is a major risk factor 
and appears to play an important role in the epidemiology and pathogenesis of infections 
(J. Kluytmans, van Belkum, & Verbrugh, 1997; von Eiff, Becker, Machka, Stammer, & 
Peters, 2001). 
 
Unfortunately, no effective licensed vaccine for S. aureus is approved till now. Thus, no 
complete protective measures are available in the community. Also, S. aureus infections 
depend on antibiotic therapy that are evolving resistance and treatment difficulties 
(Giersing, Dastgheyb, Modjarrad, & Moorthy, 2016; Spellberg & Daum, 2012). 
 
S. aureus was susceptible to many different antibiotics that have been developed. 
However, the ability to acquire antibiotic resistance mechanisms has resulted in 
epidemics and pandemics waves of antibiotic resistant S. aureus strains in the past 60 
years. Penicillin has become non-effective against S. aureus within 10 years after its 
introduction for use in people. To overcome this resistance, the semi-synthetic penicillin, 
methicillin, was developed. Yet, in 1961, only two years after methicillin was introduced, 
Methicillin Resistant Staphylococcus aureus (MRSA) was first reported in England 
(Jevons, 1961).  
 
Worldwidely, MRSA is a dangerous resistant pathogen and is considered as a major 
public health threat in both community acquired (CA-MRSA) and hospital acquired 
infection (HA-MRSA) and has become a global epidemic (Carroll, 2008; Grundmann, 
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Aires-de-Sousa, Boyce, & Tiemersma, 2006; Vindel et al., 2009; Zhang, McClure, 
Elsayed, Louie, & Conly, 2005). It is accompanied by changes in the characteristics of 
MRSA strains emerging in different parts of the world. Methicillin resistance is caused 
by reformed penicillin-binding protein (PBP). PBP is an enzyme that mediates the 
transpeptide cross-linking of the peptidoglycan of the bacterial cell wall (Chatterjee & 
Otto, 2013; Green et al., 2012; Stapleton & Taylor, 2002). This alteration in the PBP 
lowers the affinity to all the beta-lactam antibiotics; including: all penicillins, 
cephalosporins (except the fifth generation ceftaroline) and carbapenems (CDC, 2017; 
Duplessis & Crum-Cianflone, 2011).  
 
Moreover, several kinds of PBPs are involved in the resistance mechanism of MRSA 
which are encoded by the mec gene. For example, PBP2c are encoded by the mecC gene 
and PBP2a are encoded by the mecA gene which is the more common resistant gene 
among MRSA strains (Garcia-Alvarez et al., 2011). 
 
In the last two decades, exclusively, MRSA isolates have been shifted from being 
hospital associated (HA-MRSA) to community associated (CA-MRSA), which is the 
most common cause of skin and soft tissue infections (Miller & Kaplan, 2009; Talan et 
al., 2011). The emergence and increase in the incidence of CA-MRSA as an opportunistic 
pathogen occurred over the past 15–20 years with many critical implications (Chambers, 
2001; Conly & Johnston, 2003; Uhlemann, Otto, Lowy, & DeLeo, 2014). New MRSA 
clones were recognized as CA-MRSA isolates that do not only spread rapidly in 
community among healthy people, but also can cause different important and invasive 
infections in the health care related settings as well (David & Daum, 2010). Reduction in 
MRSA infections is considered as an important medical challenge, because these 
infections are associated with a serious economic burden on the healthcare resources and 
increased hospitalization costs due to the prolonged courses on more complex antibiotics 
and extended hospital days (Gould, Reilly, Bunyan, & Walker, 2010; Siddiqui & 
Whitten, 2018). 
Accordingly, epidemiologic typing of MRSA using a combination of both phenotypic 
and genotypic typing methods has contributed to the understanding of the clonal changes 
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the epidemiological distribution of MRSA among different populations. Moreover, the 
molecular characterization of MRSA is crucial to monitor and limit the occurrence and 
development of new epidemic clones of MRSA (Grubb, 1988; Montesinos, Salido, 
Delgado, Cuervo, & Sierra, 2002; Sun et al., 2013). The genotyping is also important in 
MRSA identification and correlation studies. Several studies have shown that the 
molecular epidemiology of MRSA is changing and the antimicrobial resistance rates 
associated with MRSA are increasing in the last two decades (David et al., 2008; Enright 
et al., 2002). 
1.2 Problem statement 
 
MRSA has become a real international problem everywhere. It’s a major public health 
concern in Palestine, responsible for both hospital and community associated infections. 
The increase in the prevalence of MRSA in Palestine requires special attention and 
infection control programs for protecting patients and health care workers. This includes: 
patient education, awareness of presenting signs, proper antibiotic use and appropriate 
hand and clinic hygiene. In Palestine, data on MRSA are generally rare and with 
relatively little details regarding its molecular epidemiology and common epidemic 
clones. Until recently, MRSA molecular characteristics in our region are poorly studied 
and the scale of the problem is largely unknown. 
 It is important to study the molecular characteristics and the antimicrobial susceptibility 
testing (antibiograms) of MRSA in Palestine to understand the evolutionary dynamics 
and any probable presence of significant clones or clustering in our hospitals. 
 
1.3 Study justification: 
 
The frequency of both community acquired and hospital acquired MRSA in Palestine is 
increasing. The prevalence of MRSA and the epidemic clones in Palestine is not very 
clear and need more investigations. Also, the characterization of the molecular 
epidemiology of MRSA is essential to monitor and limit the occurrence and development 
of new resistant epidemic clones of MRSA in our region. 
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1.4 Study hypotheses: 
 
1. Presence of unique MRSA clones in our hospitals. 
2. There is an association between the molecular features and the antibiograms and 
resistance trends of MRSA in West Bank-Palestine. 
3. MRSA isolates in our region have toxin genes which are related to MRSA virulence 
and invasion. 
 
1.5 Study Goal: 
 
To characterize the molecular epidemiology, virulence toxin genes and the antibiogram 
of MRSA in the West Bank-Palestine. 
 
1.6 Study aim and objectives: 
- Aim: This study aimed to investigate the epidemiological and genetic diversity of 
MRSA isolates in healthcare settings in the West Bank-Palestine, from 2015 to 2017. 
 
- Objectives:  
 
1. To study the molecular characteristics and the epidemic clones of MRSA 
strains in the West Bank-Palestine.  
2. To compare and combine the molecular features with the antibiograms and 
resistance trends of MRSA. 
3. To identify some toxin genes of MRSA which are related to MRSA virulence and 
invasion. 
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1.7 Summary of Thesis Chapters:  
 
This thesis is divided into five main chapters. The first chapter reviews an introduction 
for the study subject and describes the problem we have analyzed, showing our main 
goals and objectives. In chapter two, we have focused on the history of MRSA and how 
these resistant bacteria have developed over the years, and we have studied the most 
common methodologies that are currently used for the molecular characterization of the 
resistant genes related to MRSA. Chapter three demonstrates the detailed methodologies 
used in this study, while chapter four focuses on the results we obtained, and correlates 
our results with the patient’s antibiograms and the demographic data we could obtain 
from hospitals. In chapter five, our results and findings are discussed and compared with 
the findings of others and near countries. In the last part, we conclude our 
recommendations, strengths and limitations of this study and finally our future plans and 
goals. Chapters six and seven display the references used in this study and the 
appendices, respectively. 
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Chapter Two: 
________________________________________________________ 
Literature review 
 
2.1 History of MRSA, epidemiology and target populations: 
 
Penicillin was introduced as a medical treatment in early 1940s for most S. aureus 
infections. Few years later, resistance to penicillin and beta-lactam antibiotics has started 
to develop due to the acquisition of a plasmid and coding for penicillinase enzyme which 
cleaves the beta-lactam ring of the penicillin antibiotics (Bondi & Dietz, 1945). Now, 
more than 90% S. aureus isolates can produce the penicillinase enzyme, regardless of the 
clinical setting and become no more sensitive to this antibiotic (Lowy, 2003). 
In 1959, methicillin was introduced to overcome infections caused by S. aureus that 
produces the hydrolyzing enzyme beta-lactamase. Two years later, in 1961, first MRSA 
strain had developed quickly and spread worldwide. This development has reduced the 
therapeutic options for these bacteria (Jevons, 1961; Lowy, 2003; Parker & Hewitt, 1970; 
Schito, 2006). Initially, MRSA strains were developed only in hospitals, but in the late 
1990s, first virulent CA-MRSA clones have been detected (David & Daum, 2010). CA-
MRSA infections were related to the presence of the toxin Panton-Valentine Leukocidin 
(PVL) which had appeared rapidly and unexpectedly (DeLeo & Chambers, 2009; Enright 
et al., 2002; Green et al., 2012; Vandenesch et al., 2003). 
 
MRSA-related skin and soft tissue hospital infections have increased to double over ten 
years since 2005 (Green et al., 2012; Moran, Abrahamian, Lovecchio, & Talan, 2013). 
MRSA infections had accounted for more than 60% of nosocomial S. aureus infections in 
the intensive care units with a significant increase and change in the epidemiology of 
MRSA in US hospitals between 1992-2003 (Klevens et al., 2006). Moreover, the 
incidence of S. aureus infections increased 50% from 1999 to 2005 and  estimated to be 
about 13.8 per 1000 hospitalizations in US hospitals in 2005 (Klein, Smith, & 
Laxminarayan, 2007). Also, about 80,461 invasive MRSA infections and 11,285 related 
deaths occurred in the United States of America by 2011 with an estimated annual burden 
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of between $1.4 billion and 13.8 billion that was attributed to CA-MRSA (Abdulgader, 
Shittu, Nicol, & Kaba, 2015; CDC., 2013; Lee et al., 2013). In the European Union, it has 
been reported that MRSA infections annually affect more than 150,000 patients with high 
associated costs to the healthcare systems (Kock et al., 2010). 
 
The mecA gene provides a general resistance for many beta-lactam antibiotics, such as 
the penicillins and almost all cephalosporins (Munita & Arias, 2016). Also, a novel 
mobile genetic element called Staphylococcal Cassette Chromosome mec “SCCmec” 
element may contain genes responsible for resistance to broad spectrum antimicrobial 
agents beside the beta-lactams (Chatterjee & Otto, 2013; Ito et al., 2001; Reygaert, 2013). 
A SCCmec element was identified in a Japanese S. aureus strain at a specific site of the 
N315 chromosome in 1981 and characterized by cloning the chromosomal region 
surrounding mecA region consisting of mecA, its regulatory genes (mecI and mecR1) and 
the insertion sequence IS431(Ito et al., 2001; Ito, Katayama, & Hiramatsu, 1999; 
Katayama, Ito, & Hiramatsu, 2000), (Figure 2.1). 
 
The SCCmec is specified from other SCCs by the carriage of methicillin resistant-
determinant. The determination of the entire nucleotide sequence and subsequent 
comparison with the corresponding region of MRSA strain revealed that the mec DNA 
has a specific structure for the genetic trait of methicillin resistance. Also, the island 
SCCmec carries two site-specific recombinase homologues and was named as a new 
family of staphylococcal genomic islands and its recombinases as cassette chromosome 
recombinases A and B (ccrA and B), located at the 3’ end of orfX (Ito et al., 1999). 
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Figure 2.1: Genetic organization of the mecA gene complex in the SCCmec sequenced 
strains (N315) isolated in Japan in 1981. As shown, the SCCmec mobile element is 
characterized by mecA region consisting of mecA, its regulatory genes, mecI and mecR1, 
and the insertion sequence IS431. Also, the island SCCmec carries two site-specific 
recombinase homologues sites; the cassette chromosome recombinases A and B 
(ccrA and B), located at the 3’ end of orfX. (Source: http://www.staphylococcus.net). 
The biodiversity of novel strains and SCCmec elements has been described in recent 
years. The SCCmec types I, II and III are the most common types associated with HA-
MRSA and are rarely found among the healthy population. However, the epidemiology 
of MRSA has been developed since the 1990s with the emergence of new SCCmec 
elements; such as SCCmec types IV and V. These types (IV and V) can spread easily 
outside the hospitals, infecting not only patients, but also colonizing healthy contact 
persons (Monecke et al., 2011; Okuma et al., 2002; Xiao et al., 2002). SCCmec types IV 
and V are CA-MRSA and can harbor genes encoding the toxin Panton-Valentine 
Leukocidin (PVL) which is a serious health problem risk due to its virulence and invasion 
toxic mechanisms (Kaneko & Kamio, 2004; Watkins, David, & Salata, 2012). These CA-
MRSA types have increased mobility and the potential for horizontal spread of MRSA 
carriage or infections among populations (Albrich & Harbarth, 2008; File, 2007; Weber, 
2005). 
However, the CA-MRSA strains are more susceptible to the non beta-lactam antibiotic 
groups than the HA-MRSA strains, such as: aminoglycosides “mainly gentamicin”, 
10 
 
tetracyclines and trimethoprim-sulfamethoxazole “SXT”, (Changchien, Chen, Chen, & 
Chu, 2016; Deresinski, 2005; Lina et al., 1999; Naimi et al., 2003). 
In summary, since 1940 to 2000, four waves of antibiotic resistance in S. aureus have 
developed, as reviewed by Chambers and Deleo (Chambers & Deleo, 2009). 
Wave one began in 1940, after the introduction of penicillin and continues up to day. 
Resistant strains of wave one had produced a plasmid that encoded the enzyme 
responsible for the hydrolysis of the beta-lactam ring (essential for penicillin activity) of 
penicillin, called penicillinase. It has been found that these strains can cause both 
community acquired infections as well as hospital acquired infections, mainly by a clone 
called: phage-type 80 (Blair & Carr, 1960; Bynoe, Elder, & Comtois, 1956; Rountree & 
Beard, 1958).  
 
Wave two began in 1960, after two years upon the introduction of methicillin into clinical 
practice containing the SCCmec type I. 
 
Later on, in 1970, wave three had developed with new SCCmec types (type II & III). 
Also, in wave three, Vancomycin Intermediate Staphylococcus aureus (VISA) has 
developed due to the upsurge in Vancomycin usage for treatment of complicated MRSA 
infections. 
 
In the mid-to-late 1990s, wave four has begun with the emergence and shift to the CA-
MRSA with a new SCCmec type (type IV). Also, in wave four, in 2002 Vancomycin-
resistant Staphylococcus aureus (VRSA) strains has been first identified. Figure 2.2 
shows a timeline of the four waves of antibiotic resistance in Staphylococcus aureus as 
reviewed by (Chambers & Deleo, 2009). 
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Figure 2.2: A timeline of the four waves of antibiotic resistance in S. aureus (Chambers & Deleo, 
2009). 
 
 
 
2.2 Common methodologies used for MRSA genotyping and toxin genes profiling 
 
The application of several new molecular typing techniques depending on PCR for 
identification of MRSA strains and their gene encoding toxins gave noteworthy into the 
epidemiology of MRSA (Bukowski, Wladyka, & Dubin, 2010; Johnson et al., 1991). 
 
2.2.1 SCCmec typing: 
 
The SCCmec multiplex polymerase chain reaction (PCR) typing technique provides a 
strong evidence for the origin of MRSA, either HA-MRSA or CA-MRSA (Naimi et al., 
2003). 
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The first multiplex PCR for SCCmec typing was reported by (Oliveira, Tomasz, & de 
Lencastre, 2001). However, three clonal types (Iberian, Brazilian, and Hungarian clones) 
were previously identified as the same as the European isolates of MRSA from England 
and Denmark in which all were closely related to a common background, named as 
background A. Also, there was a completely different genetic background in New York 
and Japan known as background B. Oliveira and his colleagues have shown that three 
recently characterized SCCmec types were associated with different pandemic clones in 
which both the SCCmec types I and III were related to the MRSA isolates of genetic 
background A with few structural variations, but the SCCmec type II was associated to 
the MRSA isolates of the genetic background B. Moreover, the SCCmec type IV has 
been identified to be related to background A as well as B in some MRSA strains 
(Oliveira, Tomasz, et al., 2001).  
 
The multiplex SCCmec typing was improved in 2007 by Milheirico and his colleagues as 
a multiplex PCR involving a primer pair identifying the cassette chromosome 
recombinases (ccr) genes. They have updated a modified strategy for the method to 
identify the SCCmec types IV and V (Milheirico, Oliveira, & de Lencastre, 2007b). 
 
The multiplex PCR developed by Zhang and his colleagues is used worldwide (Zhang, 
McClure, Elsayed, Louie, & Conly, 2005). This multiplex has designed new sets of 
SCCmec types with specific primers that can detect the SCCmec types I, II, III, IV and V 
with a concomitant detection of the mecA gene which is the methicillin resistant gene and 
can serve as an internal control for more validation of the multiplex PCR and better 
identification of MRSA with  high sensitivity and specificity. This novel assay has shown 
a simple, rapid and useful typing technique for MRSA identification and epidemiological 
characterization (Zhang et al., 2005). 
By 2011, eleven major SCCmec types (I to XI) have been identified with additional 
subtypes and variants (Shore et al., 2011; Turlej, Hryniewicz, & Empel, 2011). 
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2.2.2 Staphylococcus aureus  protein A (spa) typing  
 
The spa typing method was first applied in 1987 by Pickenhahn. Now, there are about 
17641 identified spa-types with 390928 strains and 756 repeats registered in the Ridom 
spa-server, (http://www.spaserver.ridom.de) (Miao et al., 2017). 
 
Protein A is a surface binding protein which can bind the Fcγ domain of immunoglobulin  
(Ig) molecules of the host and prevent phagocytosis by the host immune system, 
promoting host immune system suppression. This makes the spa one of the major 
virulence factors of S. aureus (Falugi, Kim, Missiakas, & Schneewind, 2013; Kobayashi 
& DeLeo, 2013; Votintseva et al., 2014). The spa contains three main regions: the Fc 
binding region, the X region and the C terminal. Its whole length is 2150 bp. However, 
the spa typing technique is based on DNA sequencing of short sequence repeats (SSRs) 
of the polymorphic X region of the staphylococcal protein A gene which consists of a 
variable number of 21-bp to 27-bp repeats, with commonly 24 bp (Koreen et al., 2004). 
This typing technique has many advantages in terms of accuracy, speed, interpretation, 
reproducibility, stability and inter-laboratory comparison (Faria, Carrico, Oliveira, 
Ramirez, & de Lencastre, 2008; Ruppitsch et al., 2006). Moreover, the spa typing of 
MRSA has been found to agree with the whole genome sequencing method in a great and 
reliable percentage of 97%, as described elsewhere (Bartels et al., 2014). 
 
This method has been used for long term epidemiological and surveillance studies (Hallin 
et al., 2007). The exact function of the polymorphic X region of protein A is not well 
known, but the SSR variations are clearly related to bacterial pathogenesis, invasion to 
host tissues, evasion of the host immune system, attachment to the cell wall and virulence 
(Reischauer, Bernkopf, & Webersinke, 2010; Ruppitsch et al., 2006). However, the X 
region coding sequence in spa is a well conserved region and this allows the use of 
primers for PCR amplification and direct sequence typing (Shopsin et al., 1999). The spa 
typing has a discriminatory power for outbreak investigations and differentiation of 
different MRSA clones between different populations (Oliveira, Crisostomo, et al., 
2001). 
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2.2.3 Toxin gene profiling (PVL, TSST-1,ETA & ACME-arcA) 
 
Among multiple virulence factors, MRSA has the ability to produce several exotoxins 
which are directly associated with many diseases and symptoms.  
 
2.2.3.1 Panton-Valentine Leukocidin (PVL):  
 
PVL is one of the most critical toxins that can be produced by some MRSA strains. It 
was designated initially in 1894 by Van deVelde.  In 1932, Panton and Valentine first 
associated PVL with skin and soft tissue infection, even before the introduction of 
MRSA (Panton & Valentine, 1932). This pore-forming cytotoxin can highly cause 
leukocyte destruction and tissue necrosis. The PVL-producing MRSA strains are 
emerging as a serious problem worldwide because this leukotoxin can cause lysis of the 
leukocytes (Leukocidine), inhibiting the host immune system (Boyle-Vavra & Daum, 
2007; Melles et al., 2006). In addition, presence of  PVL toxin is not only related to 
SSTIs, but also it has been reported to be related to necrotizing lung infections and 
pneumonia with high mortality rates associated with these infections (Al-Talib, Hasan, 
Yean, Al-Ashwal, & Ravichandran, 2011). 
 
2.2.3.2 Toxic Shock Syndrome Toxin-1 (TSST-1): 
 
This toxin is considered as a superantigen and was first reported in 1978 as an exotoxin 
encoded by the tst gene. It was associated mainly with strains isolated from patients with 
toxic shock syndrome in the USA. This toxin can stimulate the hallmark features of toxic 
shock syndrome mediating fever, hypotension, rash and multi-organ dysfunction. Also, it 
can lead to host adaptive immune suppression and dysfunction (Kulhankova, King, & 
Salgado-Pabón, 2014). Experimentally, it has been found that this exotoxin can produce 
fever in rabbits and enhance susceptibility to lethal shock and death (Chatterjee & Otto, 
2013; Schlievert, Shands, Dan, Schmid, & Nishimura, 1981). 
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2.2.3.3 Exfoliative Toxins (ETs): 
 
The ETs are superantigens and also known as “epidermolytic” toxins. ETs can lead to 
hydrolysis of the superficial skin layers and proteins leading to cutaneous infections 
(Bukowski et al., 2010). 
 
There are two serologically and biologically active S. aureus exotoxins: exfoliative toxin 
A (ETA) and exofoliative toxin B (ETB) (Wiley & Rogolsky, 1977). These toxins are 
highly related to skin infections and dermatitis, especially in infants and children. 
However, it has been known that the exofoliative toxins of S. aureus, (mainly ETA), are 
responsible for the staphylococcal scalded skin syndrome (SSSS), which is also known as 
Ritters disease (Leung, Barankin, & Leong, 2018; Patel & Finlay, 2003). The SSSS is 
mainly characterized by blistering on the superficial skin layer, but does not affect the 
mucosa or deeper skin layers (Bukowski et al., 2010; Ladhani, Joannou, Lochrie, Evans, 
& Poston, 1999; Plano, Gutman, Woischnik, & Collins, 2000; Yamasaki et al., 2005). 
 
2.2.3.4 Arginine Catabolic Mobile Element (ACME): 
 
The ACME is associated with pathogenicity of the MRSA isolates which enhances both 
virulence and the ability of MRSA to colonize human skin. It is carried mainly by the 
USA-300 clone and related to the CA-MRSA of type IV (Diep et al., 2006; Mehrotra, 
Wang, & Johnson, 2000). This element is a mobile genetic element and has an important 
role in the growth and transmission of CA-MRSA strains (Watkins et al., 2012). 
However, there are two main gene clusters identified in ACME: the arc genes 
(arcA, arcB, arcC, and arcD) and the oligopeptide permease operon (opp) genes (opp-
3A, opp-3B, opp-3C, opp-3D, and opp-3E). Regarding the arc gene cluster, arcA is 
considered as a surrogate marker for ACME I (Diep et al., 2006; Miragaia et al., 2009). 
 
The routine detection for all these toxins is usually by individual PCR for toxin-encoding 
genes or random amplified polymorphic DNA analysis, as it has been described 
elsewhere (Bukowski et al., 2010; Johnson et al., 1991; Lina et al., 1999). 
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2.3 Global epidemic status of MRSA: 
 
One of the most dramatic epidemics of a single clone of CA-MRSA is that of the USA 
lineage: USA-300. This clone is a pandemic clonal lineage that is both resistant and 
highly virulent and can cause rapid tissue destructive infections in healthy young adults 
and children. It has caused great morbidity and mortality in the recent decades in USA 
(DeLeo, Otto, Kreiswirth, & Chambers, 2010). 
 
It is a community acquired clone, found first in the USA around 17 years ago, and then it 
was found in South America, Europe and Asia-Pacific region. The USA-300 clone is the 
spa type t008 characterized by the carriage of both the PVL and ACME-arcA toxin genes 
(David et al., 2013; Strauss et al., 2017). 
 
The recent emergence and spread of CA-MRSA has become a challenge even for 
countries that have so far maintained low rates of MRSA carriage (DeLeo et al., 2010). 
Continuous efforts to understand the changing epidemiology of MRSA infection in 
animals and human are necessary for appropriate antimicrobial treatment, effective 
infection control programs, and to monitor the evolution of the MRSA strains (Gould, 
2005; Stefani et al., 2012). 
 
Recently, Al Laham and his colleagues have studied MRSA clinical isolates from Gaza 
which gave a recent community widespread carriage of a the clonal complex (CC22) with 
TSST-1 gene, known as the “Gaza strain”, (Al Laham et al., 2015) 
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Chapter Three 
 
Methodology 
 
 
3.1 Bacterial strains and data collection 
 
In the present cross sectional descriptive study, a total of 112 MRSA isolates were 
collected between 16th of November 2015 and 13th of July 2017 from different 
hospitals/clinics. Major isolates were collected from “Al- Makassed Islamic Charitable 
Society Hospital” in Jerusalem. Other isolates were collected from the “Palestine 
Medical Complex” in Ramallah and “Beit-Jala Hospital” in Bethlehem. Few isolates 
were collected from the “Red Crescent Society Hospital”, “Augusta Victoria Hospital”, 
“Sehat Al-Quds” in Jerusalem , “Alia Hospital” in Hebron and from “Al-Watani 
Hospital, “Rafidia Hospital” and ‘Al-Najah Hospital” in Nablus. 
 
Samples were collected from different sources, including: wound, blood, nasal swabs, 
urine, pus,  tissue, abscesses, ear swabs, sputum and other clinical sources such as: 
axillary  swabs,  cerebrospinal fluid (CSF) culture, central venous pressure (CVP) tip 
culture, skin swabs, synovial fluid culture and trap. 
 
Demographic and clinical data including: age, sex, place of residence, date of 
administration and hospitalization, type of infection, isolate antimicrobial susceptibility 
testing, specimen origin and date of isolation were collected from medical records. 
 
3.2 Bacterial Culture and identification of MRSA strains 
MRSA isolates were identified phenotypically by colony morphology on blood agar, 
gram stain, and catalase and coagulase tests. Also, the isolates were sub-cultured on 
coagulase mannitol salt agar base (CMSA), which is recommended for the primary 
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isolation and differentiation of pathogenic Staphylococci from specimens or for 
classifying pure cultures (HIMEDIA, 2011). This medium is a selective medium for 
Staphylococci and differential for S. aureus from the other coagulase negative 
Staphylococci on the basis of coagulase production and mannitol fermentation by which 
the medium turns yellow and turbid as coagulase positive S. aureus grows on.  
 
The strains of methicillin resistant S. aureus were detected by the disk agar diffusion 
method using a cefoxitin disk/30μg (FOX) on Mueller-Hinton agar plates (MH), 
incubated at 350C for 24h; a zone of inhibition ≤ 22 mm is considered as resistant 
according to the Clinical Laboratory Standards Institute (CLSI) guidelines (CLSI, 2017). 
This was done mostly by the hospitals and confirmed for some isolates in our lab. 
 
At the molecular level, the strains of MRSA were confirmed by the detection of  mecA 
“methicillin resistant” gene as described elsewhere (Geha, Uhl, Gustaferro, & Persing, 
1994), using the following primers: mecA1F (5’-
GTAGAAATGACTGAACGTCCGATAA-3’) and mecA2R (5’-
CCAATTCCACATTGTTTCGGTCTAA-3’), yielding to 310-bp amplicons. Isolates that 
were confirmed to be methicillin sensitive by the disk diffusion method then by the 
absence of the mecA gene were excluded from this study, whereas, only MRSA isolates 
were included and characterized at the molecular level. 
 
3.3 Antimicrobial Susceptibility Testing 
 
The antimicrobial susceptibility testing was determined for few isolates by the hospitals 
using the Kirby-Bauer disk diffusion method according to CLSI recommendations (CLSI, 
2017). However, the antimicrobial susceptibility testing full profile was missing or not 
provided for most isolates. Then, it was done in our lab following the same guidelines 
and instructions. The susceptibility for the following antibiotics:  cefoxitin, penicillin G, 
amoxicillin/clavulanic acid, ceftriaxone, meropenem, vancomycin, erythromycin, 
clindamycin, gentamicin, SXT, and ciprofloxacin were determined. Isolates were 
considered to be susceptible isolates when the bacterial zones of inhibition confirmed to 
19 
 
the susceptibility category for a given antibiotic as provided in the CLSI (2017) manual. 
If isolates were susceptible to cefoxitin, they were excluded from the study. Isolates were 
defined as multidrug resistance strains (MDR) when they were resistant to at least three 
different antibiotic groups (non-β-lactam groups) in addition to resistance to the β-lactam 
antibiotics (Magiorakos et al., 2012). The D-test was performed to test the inducible 
resistance to clindamycin as needed. 
 
3.4 Freezing of MRSA Isolates 
 
The pure fresh isolates of MRSA were streaked on blood agar to be inoculated, then, in 
bacterial preserver vials containing 25% glycerol at -80°C until needed. 
The freezing solution was prepared as the following: 37.8 gram of brain heart infusion 
broth (BHI) were weighed and suspended in a graduated cylinder with ddH2O till 750mL. 
The solution was mixed well to become homogenous and 250 mL of pure glycerol were 
added. Then, the mixture was mixed well and autoclaved. After autoclaving, each 1 mL 
of the prepared freezing mixture was aliquoted in a screw capped sterile eppendrof tubes 
and freezed at -30°C to be used for the collected isolates. 
 
3.5 DNA Extraction and Quantification 
 
Genomic DNA was extracted from overnight fresh cultures by boiling method as 
described by Biber and his collegues (Biber et al., 2015) and/or by using the DNA 
extraction kit “Nucleospin, Macherey-Nagel , Germany” (NucleoSpin®, 2017). 
 
For the extraction by boiling, a loopful suspension of overnight grown cultures on blood 
agar plates was prepared in a 1.5 mL microcentrifuge tube containing a prepared lysis 
solution of 95 μL of sterile nuclease free distilled water,  1 μL lysostaphin (1 mg/mL), 1 
μL lysosyme (1mg/mL), 1 μL 1M Tris and 2 μL 0.5M EDTA. The suspension was first 
incubated at room temperature for 5 min. Then, incubated at 370C for 30 min and then 
heated in dry bath incubation at 950C for 10 min. The suspension was centrifuged at 
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10,000 rpm for 5 min; the supernatant was collected in a new clean collection microfuge 
tube and used as DNA template. 
 
For the extraction by the Nucleospin Kit, it was done according to the manufacturer’s 
instructions with some modifications. Briefly, 2-3 pure colonies were suspended in 180 
μL T1 buffer and 25 μL Proteinase K solution. Samples were completely covered with 
this lysis solution and colonies were lysed by vigorous vortex yielding to a turbid 
mixture. T1 buffer and Proteinase K mixture are stable for 10–15 min before addition of 
samples because proteinase K tends to self-digest in T1 buffer without substrate. Thus, it 
was pre-mixed directly before use only. However, it is important to add proteinase K to 
digest proteins and remove contamination from preparations of nucleic acid. Then, the 
mixture was incubated in a shaking incubator overnight at 56°C until complete lysis is 
obtained. After lysis, 200 μL of B3 buffer were added to each sample, vortexed 
vigorously and incubated at 70 °C for 15 min. Then, after incubation, samples were 
vortexed vigorously and adjusted for the DNA binding step. Then, 210 μL absolute 
ethanol (96–100 %) were added to each sample, vortexed vigorously, and loaded to the 
NucleoSpin® Tissue Column silica membrane with the collection tube, provided by the 
kit. Then, samples were centrifuged for 1 min at 11,000 x g and first wash was done by 
adding 500 μL BW buffer and centrifuged for 1 min at 11,000 x g. After centrifugation, 
the flow through solution was discarded and columns were placed into new collection 
tubes. Second wash was done by adding 600 μL B5 buffer to the column and 
centrifugation for 1 min at 11,000 x g. Then, the flow through solution was discarded and 
the silica membrane columns were allowed to dry by centrifuging the columns with the 
collection tubes for 1 min at 11,000 x g. Residual ethanol is removed during this step. 
The final step, the elution step was modified to yield to high pure and high concentration 
DNA. Half volume of elution buffer (50 μL) was added to the column and incubated for 
10 min at room temperature before centrifugation. The elution buffer was pre-heated at 
60°C to dissolve the pellet well. After centrifugation, the second half of the elution buffer 
(50 μL) was added to the column and incubated, also, for 10 min at room temperature, 
then centrifuged again. By this, about 85–100 % of bound nucleic acid is eluted in the 
standard elution volume and at a high concentration.  
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The extracted DNA by the two methods was stored at –30°C for the molecular analysis. 
The concentration and purity of DNA were measured by (Nanodrop 1000 
spectrophotometer; ThermoScientific). The instrument was adjusted using 1μL distilled 
water as a blank for the boiling method and the kit elution buffer as a blank for the 
Nucleospin kit extraction method. The protein/ DNA ratio (260/280 nm) was measured to 
estimate the purity of DNA samples. Whereas, samples with purity less than 1.2 were not 
used and re-extracted again. The boiling method was faster and simpler, but the DNA 
extraction by kit had shown higher purity and better stability of the DNA upon storage 
for further use. 
 
The DNA concentrations used for molecular typing of all samples ranged between 20-
200 ng/μL. However, the volume of template DNA was increased for samples with low 
concentration and the highly concentrated DNA samples were diluted with nuclease free 
distilled water for better yield and purity. Figure 3.1 (A) shows a summarized table taken 
as a snapshot from the Nanodrop 1000 spectrophotometer, for some representative 
randomly selected extracted samples that were used as template DNA for the genotyping 
profile. Figure 3.1 (B) shows a representative graph for an extracted DNA sample 
measured by the Nanodrop. 
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Figure 3.1: A: A table taken as a snapshot from the (Nanodrop 1000 spectrophotometer) 
for some representative randomly selected extracted samples that were used as template 
DNA for the genotyping profile. B: A graph of a representative extracted DNA sample as 
examined on the Nanodrop 1000 spectrophotometer. 
 
 
3.6 Molecular characterization of the strains: Typing of isolates: 
 
3.6.1 PCR identification of staphylococcal cassette chromosome (SCCmec) types: 
 
SCCmec types (I–V) were identified by multiplex PCR amplification of the SCCmec 
region as described by others (Boye, Bartels, Andersen, Moller, & Westh, 2007). Table 
3.1 shows the primers used in the multiplex PCR for the SCCmec typing. 
 
A 
B 
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Table 3.1: Primer sequences and target amplicons used for the SCCmec typing used in 
this study. 
 
# Primer name/target* Primer sequence (5’-3’) length/bp3 
1 
β/ccrA2F1-B ATTGCCTTGATAATAGCCYTCT 
937 
α3/ccrA2R2-B TAAAGGCATCAATGCACAAACACT 
2 
ccrCF/ccrC CGTCTATTACAAGATGTTAAGGATAAT 
518 
ccrCR/ccrC CCTTTATAGACTGGATTATTCAAAATA 
3 
1272F1/IS1272 GCCACTCATAACATATGGAA 
415 
1272R1/IS1272 CATCCGAGTGAAACCCAAA 
4 
5RmecAF/IS431 TATACCAAACCCGACAACTAC 
359 
5R431R/IS431 CGGCTACAGTGATAACATCC 
*: These primers were used as described by (Boye et al., 2007). 
1F: Forward primer; 2R: reverse primer,3bp: base pair. 
 
The multiplex PCR mixture was prepared by diluting each stock primer (100µM) 
described above in table 3.1, as the following: 1:20 to get 5µM from primer β/α3, 1:16 to 
get 6.25 µM from primer ccrCF/ccrCR, 1:50 to get 2 µM from primer 1272F1/1272R1 
and 1:40 to get 2.5 µM from primer 5RmecA/5R431.  
 
Multiplex PCR reaction was carried out in a total volume of 25 µL using PCR-Ready 
Products™ from Syntezza (Syntezza, 2004) or Thermo Scientific PCR Master Mix with 
1µL from each diluted primer and 2 µL from template DNA. When using the Thermo 
Scientific PCR Master Mix, 12.5 µL from this mix were taken with 2.5 µL dd H2O. 
However, when Syntezza was used, 15 µL dd H2O with 1µL from each diluted primer 
were mixed in the Syntezza tubes. The multiplex reaction conditions for SCCmec typing 
using either Syntezza or Thermo Scientific PCR Master Mix are is summarized in table 
3.2. 
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Table 3.2: Multiplex reaction conditions for SCCmec typing using either Syntezza or 
Thermo Scientific PCR Master Mix. 
Reagents Syntezza Mix/µL 
Thermo 
Master 
Mix/µL 
Primers (100 µM) 
1:20 primer β/α3 1 µL F2 + 1 µL R3 
1:16 primer ccrCF2/ccrCR3 1 µL F + 1 µL R 
1:50 primer 1272F1/1272R1 1 µL F + 1 µL R 
1:40 primer 5RmecA/5R431 1 µL F + 1 µL R 
Ultra-pure ddH2O1 
 
15 µL 2.5 µL 
DNA template 
 
2 µL 
Thermo Master Mix 
 
--- 12.5 µL 
Final volume/ μL 
 
25 µL 25 µL 
The samples were mixed well; then, the tubes were placed in a thermal cycler using 
program no.2 in table 3.5. 
 
1: Deionized distilled water; 2F: Forward primer; 3R: reverse primer. 
 
The SCCmec type was determined according to the amplicon banding patterns and length 
obtained, as described in table 3.3. When the type was not determined or confirmed by 
multiplex, individual PCR was performed for each primer pair alone. If isolates could not 
be assigned to types (I–V), they were grouped into SCCmec non-typeable (NT). That 
means that this isolate does not agree to be any of the examined types (I-V). 
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Table 3.3: Gel band patterns and lengths for the multiplex SCCmec typing used in this 
study. 
Multiplex SCCmec typing Types 
# Primers1 Length/bp I II III IV V NT2 
1 β/ α3 937 -- X -- X -- -- 
2 ccrCF/ccrCR 518 -- -- X -- X -- 
3 1272F1/1272R1 415 X -- -- X -- -- 
4 5RmecA/5R431 359 -- -- -- -- X -- 
1: This multiplex and its interpretation were taken from (Boye et al., 2007). 
2: Non-typeable. 
 
 
3.6.2 PCR identification of spa types: 
 
All bacterial isolates were characterized by spa sequence-based typing as described by 
(Shopsin et al., 1999), using the following primers: 1095F/spa-F (5’-
AGACGATCCTTCGGTGAGC -3’) and 1017R/spa-R (5’-
GCTTTTGCAATGTCATTTACTG -3’). All spa amplicons were sequenced and 
analyzed using the spa Type Finder/Identifier: (http://spatyper.fortinbras.us/). 
 
3.6.3 Sequencing of spa amplicons: 
 
All spa positive PCR products detectable by gel electrophoresis were sequenced. DNA 
sequencing was performed at the Hylabs sequencing service/ Jerusalem, Israel. The 
chromatograms were checked and the obtained sequences were assembled by the Bioedit 
software. The spa sequences were aligned with each other using the Multalin Multiple 
sequence alignment tool (http://multalin.toulouse.inra.fr/multalin/). 
For clustering of spa types and grouping in spa-clonal complexes (spa-CC), the Based 
Upon Repeat Pattern (BURP) algorithm of the Staph-Type™ software was used (Ridom 
GmbH, Münster, Germany). Multi-locus sequence typing (MLST) clonal complexes 
(CC) corresponding to the respective spa-CCs were assessed from the SpaServer website 
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(www.spaserver.ridom.de) as it was demonstrated that there is a high concordance 
between BURP and MLST-based clustering results (Biber et al., 2015; Harmsen et al., 
2003; Strommenger et al., 2008), this was based on the sequencing results, the spa typer 
server mentioned above and the available MLST data on the MLST database 
(http://saureus.mlst.net). 
 
The BURP is an automated tool that can provide us with evolutionary signals by 
clustering the related clones “from the spa typing repeat regions” together as clonal 
complexes (CCs) for many different  types (Mellmann et al., 2007). However, this 
method cannot provide full and optimal data for the MLST-CCs, but can be sufficient for 
short term and immediate goals. 
 
The Ridom Staphtype is an excellent software tool allowing rapid classification and 
repeat determination of isolates into the particular clonal lineages. This typing technique 
is very helpful for short term local epidemiological studies for MRSA as well as for 
international surveillance studies, long term epidemiological studies and outbreak 
investigations (Strommenger et al., 2008).  
 
3.6.4 Phylogenetic Analyses 
 
Following DNA amplification and sequencing, a phylogenetic tree was constructed to 
determine the relationships between MRSA isolates based on the obtained spa gene data.  
Phylogenetic analyses of the spa sequences were performed by the Unweighted Pair 
Group Method with Arithmetic Mean (UPGMA) applying the neighbor joining and 
maximum likelihood algorithms. Phylogenetic tree analysis was conducted all the 
sequences as a FASTA format (https://www.ebi.ac.uk/Tools/sfc/emboss_seqret/) to the 
Multiple Sequence Alignment by CLUSTALW; (http://www.genome.jp/tools-
bin/clustalw). The reliability of internal branches was assessed by bootstrapping with 
1000 pseudo-replicates. Nodes with bootstrap support less than 70% were collapsed. 
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3.6.5 PCR identification of staphylococcal genes for virulence factors 
Genes for virulence factors, namely PVL cytotoxin genes (lukS and lukF), which produce 
the  PVL cytotoxin causing leukocyte destruction and tissue necrosis, TSST-1, ETA, and 
ACME-arcA, were tested for all of the isolates. 
All bacterial isolates were characterized for the PVL toxin, using primers: luk-PV-
1F/PVL (5’-ATCATTAGGTAAAATGTCTGGACATGATCCA-3’) and luk-PV-
2R/PVL (5’- GCATCAASTGTATTGGATAGCAAAAGC-3’). For the TSST-1, the 
following primers: GTSSTR-1F (5’-ACCCCTGTTCCCTTATCATC-3’) and GTSSTR-2R 
(5’- TTTTCAGTATTTGTAACGCC-3’) were used. For the ETA toxin, the following 
primers: GETAR-1F (5’-GCAGGTGTTGATTTAGCATT-3’) and GETAR-2R (5’-
AGATGTCCCTATTTTTGCTG-3’) were used, and for the ACME-arcA toxin using the 
following primers: arcA-F (5’-GAGCCAGAAGTACGCGAG-3’) and arcA-R (5’- 
CACGTAACTTGCTAGAACGAG-3’). These toxins were identified by individual PCR 
amplification yielding to: 433bp, 350bp, 93bp and 724 bp, respectively, as described 
elsewhere (Lina et al., 1999; Mehrotra et al., 2000; Vento et al., 2013). 
The seven target genes, their primer sequences and amplicons length used in the 
molecular characterization of each MRSA strain in this study are summarized in table 
3.4. 
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Table 3.4: All Target genes and primers used in this study. 
 
# Gene  Oligo1Name Primer sequence 5’-3’ Length (bp) Ref.
2 
1 mecA 
mecA1F3 GTAGAAATGACTGAACGTCCGATAA 
310 
(Geha et 
al., 
1994) mecA2R4 CCAATTCCACATTGTTTCGGTCTAA 
2 
SCCmec 
multiplex 
"4 
primers" 
β/ccrA2F-B ATTGCCTTGATAATAGCCYTCT 
937 
(Ito et 
al., 
2001) α3/ccrA2R-B TAAAGGCATCAATGCACAAACACT 
ccrCF/ccrC CGTCTATTACAAGATGTTAAGGATAAT 
518 
(Ito et 
al., 
2004) ccrCR/ccrC CCTTTATAGACTGGATTATTCAAAATA 
1272F1/IS1272 GCCACTCATAACATATGGAA 
415 (Boye et 
al., 
2007) 
1272R1/IS1272 CATCCGAGTGAAACCCAAA 
5RmecAF/IS431 TATACCAAACCCGACAACTAC 
359 
5R431R/IS431 CGGCTACAGTGATAACATCC 
3 Spa 
1095F/spa-F AGACGATCCTTCGGTGAGC 
200-400 
(Shopsin 
et al., 
1999) 1017R/spa-R GCTTTTGCAATGTCATTTACTG 
4 PVL 
luk-PV-1F/PVL ATCATTAGGTAAAATGTCTGGACATGATCCA 
433 
(Lina et 
al., 
1999) luk-PV-2R/PVL GCATCAASTGTATTGGATAGCAAAAGC 
5 TSST-1 
GTSSTR-1F ACCCCTGTTCCCTTATCATC 
350 
(Mehrotr
a et al., 
2000) GTSSTR-2R TTTTCAGTATTTGTAACGCC 
6 ETA 
GETAR-1F GCAGGTGTTGATTTAGCATT 
93 
(Mehrotr
a et al., 
2000) GETAR-2R AGATGTCCCTATTTTTGCTG 
7 ACME-arcA 
arcA-F GAGCCAGAAGTACGCGAG 
724 
(Vento et 
al., 
2013) arcA-R CACGTAACTTGCTAGAACGAG 
1Oligo: Oligonecleotide;2:Reference,3F: Forward primer; 4R: reverse primer. 
 
3.7 PCR Conditions: 
 
All PCR amplification methods were optimized for each target gene in this study. PCR 
reactions were carried by the (Biometra TProfessional Basic Gradient Thermocycler). In 
all amplification reactions, both negative controls (mix without DNA) and positive 
controls (from pervious runs of PCR’s in this study) were included. 
All thermal cycler programs used for amplification of the target genes and toxins in this 
study are summarized in table 3.5. 
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Table 3.5: Thermal cycler programs used for the amplification of the targeted genes and 
toxins in this study. 
 
*: These PCR programs were taken as described in their references for each gene mentioned earlier in table 
3.4 and optimized to be used in this study too. 
**:  This initial denaturation time was used for Thermo Master Mix. Otherwise, when Syntezza tubes were 
used, initial denaturation temperature was modified for 5 min. 
1Temp: Temperature ,2min: Minutes, 3sec: Seconds. 
 
 
 
3.8 Agarose gel electrophoresis: 
 
Amplicons for all the characterized genes were analyzed electrophoretically in  2% 
agarose gels (SeaKem® LE agarose gel), run at 120 V in 1x -Tris -Acetate –EDTA buffer 
(TAE), prepared as described in the appendix, containing ethidium bromide  (0.5 g/mL) 
for visualization  by UV light using a gel documentation system (the Bio-Imaging 
Systems MiniLumi transilluminator). A 100 bp or 1Kb molecular weight standard ladders 
(ThermoScientific GeneRuler) was used as molecular weight standards for each gel.  
 
 
 
 
 
 
# Target Gene 
PCR Program (Temp1°C/ Time)* 
Cycles 
Initial 
denaturation** Denaturation Annealing Extension 
Final 
extension 
1 mecA 95°C /15 min2 95°C /30 sec3 58°C/30 sec 72°C/80 sec 72°C/10 min 35 
2 SCCmec 95°C /15 min 94°C /30 sec 55°C/30 sec 72°C/80 sec 72°C/10 min 35 
3 Spa 95°C /15 min 95°C /30 sec 58°C/30 sec 72°C/45 sec 72°C/10 min 35 
4 PVL 95°C /15 min 95°C /45 sec 55°C/15 sec 72°C/30 sec 72°C/10 min 35 
5 TSST-1 95°C /15 min 95°C /2 min 54°C/2 min 72°C/2 min 72°C/10 min 35 
6 ETA 95°C /15 min 95°C /2 min 54°C/2 min 72°C/2 min 72°C/10 min 35 
7 arcA 95°C /15 min 94°C /20 sec 55°C/30 sec 72°C/30 sec 72°C/10 min 35 
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3.9 Ethical Considerations 
The study was approved by the Research Ethical Committee at Al-Quds University. Also, 
a permission from the Palestinian Ministry of Health (MOH) was obtained to review the 
clinical reports of patients and to collect the demographic data of patients. Written 
informed consents were sent for the participating hospitals and clinics. 
 
3.10 Statistical Analysis 
Each isolate was coded, and data were entered and analyzed using the Statistical Package 
for Social Sciences (SPSS) version 20. Descriptive statistics for all samples were 
presented as frequencies and percentages. The distribution of MRSA isolates in clinical 
samples was analyzed. The associations between the SCCmec type, spa type and MLST-
CCs with the arcA, ETA, TSST-1 and PVL genes were analyzed using Chi-square test. A 
p-value of <0.05 was considered to be statistically significant. 
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Chapter Four:  
 
Results 
4.1 Bacterial isolates and Study population 
From November 2015 to July 2017, 112 MRSA isolates were collected from ten hospitals 
and clinics distributed among five different Palestinian regions (Jerusalem, Ramallah, 
Nablus, Bethlehem and Hebron). 
In fact, the highest number of isolates was collected from Al-Makassed Islamic 
Charitable Hospital (77, 68.8%) and twelve isolates from the Palestine Medical Complex 
(12, 10.7%). Other isolates were collected from the hospitals as shown in figure 4.1.  
Eighty four isolates (75%) were collected from hospitals and clinics in Jerusalem and its 
suburbs, as the following: (77, 68.8%) from Al- Makassed Islamic Charitable Society 
Hospital, four isolates from Red Crescent Society Hospital (3.6%),  two isolates from 
Augusta Victoria Hospital (1.8%) and one isolate from Sehat Al-Quds in Bethany (0.9%).  
 
Twelve isolates were collected from the Palestine Medical Complex (10.7%) in Ramallah 
and  seven isolates (6.2%) from Nablus hospitals distributed between three hospitals, as 
the following: four isolates from Al-Najah Hospital (3.6%), two isolates from Al-
Watani/Nablus Hospital (1.8%) and one isolates from Rafidia Hospital (0.9%). Other 
isolates were collected from Beit Jala Hospital (6, 5.4%) and Hebron Hospital (3, 2.7%). 
Figure 4.2 displays a map of Jerusalem (Al-Quds) and the West Bank showing the 
distribution of MRSA isolates among hospitals which are included in this study, 
indicating the sampling area. 
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Figure 4.1: Number of isolates and their distribution among hospitals as collected in this 
study.  
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Figure 4.2:  A map of Jerusalem (Al-Quds) and the West Bank showing the distribution 
of MRSA isolates among hospitals which are included in this study (Sampling area). 
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Full demographic data for each isolate including: the hospitalization period, age group, 
patient type, gender, place of residence, department and source were available for 82 
(73.2 %) of these patients.  
Place of residence for all included patients was documented from the archive section. The 
most frequent regions of the collected isolates were from Gaza and Jerusalem (33, 29.5% 
for each), followed by the Hebron (15, 13.4%), Nablus (12, 10.7%), Ramallah (12, 
10.7%), Bethlehem (5, 4.5%), Tubas (1, 0.9%) and Tulkarem (1, 0.9%), (figure 4.3). 
However, isolates which were obtained from Gaza’s patients were referred to Al-
Makassed Islamic Charitable Society Hospital in Jerusalem. 
 
 
Figure 4.3: Number of patients and their place of residence as collected in this study.  
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According to gender, of all the 112 cases diagnosed as MRSA, 60 (53.6%) were males 
and 41(36.6%) were females, with high significant association with gender (p<0.05). 
However, gender of 9.8% (n=11) of the isolates were not found (Figure 4.4). 
 
 
Figure 4.4: MRSA distribution according to gender. 
  
 
Cases were of all ages. Figure 4.5 shows the age distribution. The mean age was 33 years 
(median: 30 years; interquartile range: 42 years), with the oldest case being a 85 years old 
female and the youngest a two months year old female. Age was categorized to four age 
groups, as the following: Infant; from 0-1 year, children; from 1-10 years, adolescent; 
from 10-19 years and as adult; more than 19 years. 
 
The most common age group of isolates collected in this study was the adults (68, 
60.7%), followed by the adolescents (16, 14.3%), infants (10, 8.9%) and children (8, 
7.1%). Age was not found for 8.9% of the samples, (Figure 4.5). 
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Figure 4.5: Distribution of age groups of patients that isolates were collected from during 
this study.  
 
 
Combining gender with age groups showed that adult males (aged>19 years) were 
significantly at the highest risk (p<0.05), followed by adult females, then adolescent 
males (aged between 10-19 years). (Table 4.1). 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
Adult
(>19 yrs)
Adolescent
(10-19 yrs)
Infant
(0-1 yrs)
Child
(1-10 yrs)
NF*
no
. o
f i
so
la
te
s 
Age group 
14.3% 
8.9% 7.1% 
60.7% 
*: Not Found 
8.9% 
37 
 
Table 4.1: Relationship between gender and age groups of MRSA isolates in this study. 
 
Gender 
Age Group 
Total Adult      
>19yrs 
Adolescent    
10-19yrs 
Infant       
0-1yrs 
Children   
1-10yrs 
Not 
found 
Male 38 14 3 4 1 60 
Female 29 1 6 4 1 41 
Not found 1 1 1 0 8 11 
Total 68 16 10 8 10 112 
 
 
More than half of the patients were hospitalized (in-patients, 67.9%). Whereas, (23.3%) 
were out patients that have been admitted to the emergency or the day care clinics and 
discharged within the same day. Dialysis patients were considered as in-patients in which 
they are under healthcare facilities and medical devices exposure. Data for 10 isolates 
(8.9%) were missing, (Table 4.2). 
 
Table 4.2: Patient types of the study population. 
 Patient type No. of isolates (n) Percentage % 
1 In-patient 76 67.9 
2 Out-patient 26 23.2 
3 NF1 10 8.9 
 Total 112 100 
1: Not Found. 
 
The MRSA isolates were collected from different wards and areas in the hospitals. The 
highest number of cases were  from the orthopedic ward (17.9%), followed by the 
surgery and neurosurgery wards (17.0%), the daycare or the out-clinics (11.6%), the 
emergency (8.9%), the Intensive Care Unit (ICU) (8.9%), the pediatric ward (8.0%) and 
other wards (8.9%), as the follows: the medical ward (2.6%), dialysis (1.8%), gynecology 
(1.8%), holding area (1.8%) and the Cardiac Care Unit (CCU) (0.9%). Data for 21 
isolates (18.8%) were missing, (Table 4.3). 
 
38 
 
Table 4.3: Distribution of the MRSA isolates among the different hospital wards. 
 
 
Wards No. of isolates (n) Percentage % 
1 Orthopedic ward 20 17.9 
2 Surgery & Neurosurgery wards 19 17.0 
3 Daycare 13 11.6 
4 Emergency 10 8.9 
5 ICU 10 8.9 
6 Pediatric ward 9 8.0 
7 Others1 10 8.9 
8 NF2 21 18.8 
 
Total 112 100 
1: Other wards include: The medical ward, dialysis, gynecology, holding area and the CCU ward, (n=3, 2, 2, 
2, and 1) respectively.  
2: Not Found. 
 
 
Samples were collected from fifteen different clinical sources. The highest number of 
isolates were obtained from wound infections (35.7%), followed by: blood culture 
(12.5%), nasal swabs (8.9%), urine culture (8.9%), pus culture (5.4%), tissue culture 
(4.5%), abscess (3.6%), ear swabs (2.7%), sputum culture (2.7%) and other sources 
(5.4%), as the follows: axillary swab (0.9%), CSF culture (0.9%), CVP culture (0.9%), 
skin swab culture (0.9%), synovial fluid culture (0.9%), and trap (0.9%). Source of 
eleven isolates (9.8%) was not identified. Figure 4.6 summarizes the distribution of the 
different sources of MRSA isolates. 
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Figure 4.6: The distribution of the different sources of MRSA isolates that have been 
involved in this study.  
 
 
 
4.2 Detection of MRSA by cefoxitin disk diffusion test and mecA gene 
 
All of the 112 isolates (100%) were identified as Methicillin Resistant Staphylocoocus 
aureus using the cefoxitin disc resistance (<22mm) and confirmed as “MRSA” using 
PCR targeting the mecA gene. Cefoxitin resistance was 100 % correlated with mecA gene 
presence. Figure 4.7 displays representative Mueller Hinton agar plates for the detection 
of MRSA isolates by the disk diffusion method showing the resistance pattern to 
cefoxitin. Figure 4.8 is a gel electrophoresis for the detection of the mecA gene for 
representative MRSA isolates in this study. 
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Figure 4.7: The disk diffusion method for the detection of MRSA. Two representative 
MH plates (A & B) showing the resistance pattern to cefoxitin (red arrows) by MRSA 
isolates. 
 
A 
B 
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Figure 4.8: A representative agarose gel electrophoresis for the mecA gene detection in 
MRSA. Lanes 1-12: mecA positive MRSA isolates. Lane 13: positive control. Lane 14: 
negative control. M: 100 bp DNA molecular weight marker. Band size is around ~310 
bp. 
 
4.3 Antimicrobial susceptibility patterns: 
 
All isolates were tested for susceptibility patterns to the 11 antibiotics. Aside from 
cefoxitin, high rates of resistance of MRSA isolates against penicillin G, 
amoxicillin/clavulanic acid, ceftriaxone and meropenem were noticed (100%) and  
resistance with variable degrees to erythromycin, ciprofloxacin, clindamycin were  
63.4%, 39.3%, 34.8%, respectively. On other hand the susceptibility of MRSA isolates to 
gentamicin and SXT was high (76.8%, 81.3%), respectively. All isolates were susceptible 
to Vancomycin (100%). Of all the isolates, 32 (28.6%) were multi-drug resistant (MDR). 
These isolates were resistant to at least three different non-β-lactam antibiotic groups, 
(Figure 4.9). 
 
Among the 32 MDR isolates, the highest rates were from wound (34%) and blood 
cultures (16%), followed by: urine (13%), nasal swabs (10%) and tissue cultures (6%). 
The other MDR isolates were from abscess (3%), axillary swab (3%), pus (3%) and CVP 
tip culture (3%).  Other three isolates were MDR but their source were not available 
(9%), (Figure 4.10). 
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Figure 4.9: Antimicrobial resistance rates among all MRSA isolates in this study. 
 
 
 
Figure 4.10:  Distribution of the MDR isolates according to source.   
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4.4 Molecular characterization and typing of isolates 
4.4.1 SCCmec typing: 
Strong and easily banding patterns were obtained for most of the SCCmec types using the 
multiplex PCR, (Figure 4.11). Among the 112 MRSA isolates, ninety seven isolates were 
belonged to SCCmec type IV (86.6%), ten isolates were belonged to SCCmec type I 
(8.9%) and one was belonged to SCCmec type V (0.9%). Four MRSA isolates (3.6%) 
could not be SCCmec typed and designated as non-typeable (NT). All the NT isolates 
were retested, using the same primer set of SCCmec multiplex PCR, but as individual 
PCR. Both SCCmec type II and SCCmec type III were not detected among isolates. 
SCCmec type V was detected only in one isolate by multiplex PCR and more confirmed 
by individual PCR as shown in figure 4.12. 
 
 
 
Figure 4.11: A representative agarose gel electrophoresis for the multiplex SCCmec 
typing for some representative isolates involved in this study. Lanes 1-9: SCCmec type 
IV (2 bands: at 937 bp & 415 bp). Lanes 10-13: SCCmec type I (1 band at 415 bp). Lane 
14: negative control. M: 100 bp DNA molecular weight marker. 
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Figure 4.12:  The SCCmec type V that was detected in only one isolate in this study. 
Lane 1: the multiplex SCCmec PCR (bands at 518 & 359 bp; this is related to SCCmec 
type V. Lane 3: individual PCR for the 518 bp target alone. Lane 5: individual PCR for 
the 359 bp target alone. Lane 2: the negative control for the multiplex PCR. Both lane 4 
& 6 are the negative controls for each individual PCR alone. 
 
Among all community-onset isolates, CA-MRSA was defined as isolates carrying the 
SCCmec types IV or V. In our study, the most common SCCmec type was SCCmec type 
IV (86.6%) which is considered as a CA-MRSA type. Ten MRSA isolates were found to 
be related to the SCCmec type I that is considered as a HA-MRSA type (8.9%), Figure 
4.13 shows the distribution of the SCCmec types as found in this study. 
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Figure 4.13: The distribution of the SCCmec types as found in this study.  
 
4.4.2 Spa typing: 
 
A total of twenty nine spa types were identified. Four isolates (3.6%) were non-typeable 
(err) and negative by spa typing PCR. One sequenced isolate gave a not identified spa 
type (*) on the spa database website (http://spatyper.fortinbras.us/), after  sequencing the 
PCR product from both sides, using forward and reverse primers. 
The size of the amplified DNA for spa typing ranged between 200-450 bp. The four (err) 
spa negative samples were re-tested from new subcultures and new re-extracted DNA, 
but remained negative even with different optimizations. In addition, these isolates were 
confirmed to be negative in laboratories of Sheba Medical Center, Tel-Hashomer, Israel.  
Figure 4.14 shows the gel electrophoresis for spa PCR for some representative isolates 
with the bands variation in size as found in this study. It has been found that different 
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band sizes mostly have different spa types; (different short sequence repeats of the 
polymorphic X region of the staphylococcal protein A gene). 
 
 
Figure 4.14: A representative agarose gel electrophoresis for the spa typing PCR with 
the different band sizes for some representative samples involved in this study. Lane 1-8: 
spa positive samples. Lanes 9-11: spa non-typeable isolates found in this study. Lane 12: 
negative control. M: 100 bp DNA molecular weight marker. 
 
Five spa types: t386, t008, t044, t223 and t037 were predominant and represented 14 
(12.5%), 12 (10.7%), 12 (10.7%), 11 (9.8%), 10 (8.9%) isolates, respectively. They were 
followed by the spa types: t021 (7, 6.3%), t991 (6, 5.4%), t002 (4, 3.6%), t1516 (4, 
3.6%), t131 (3, 2.7%), t304 (3, 2.7%), t688 (3, 2.7%) and t104 (2, 1.8%). The other 
sixteen spa-types: t005, t011, t018, t084, t085, t1094, t121, t1247, t127, t314, t318, t359, 
t541, t605, t648 and t932 were found in a frequency of one for each isolate (1, 0.9%), 
(Table 4.4).  
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Table 4.4: All the spa-types found in this study by spa typing. 
 
spa-type No. of isolates (n) Percentage % 
1 t386 14 12.5 
2 t008 12 10.7 
3 t044 12 10.7 
4 t223 11 9.8 
5 t037 10 8.9 
6 t021 7 6.3 
7 t991 6 5.4 
8 t002 4 3.6 
9 t1516 4 3.6 
10 t131 3 2.7 
11 t304 3 2.7 
12 t688 3 2.7 
13 t104 2 1.8 
14 t005 1 0.9 
15 t011 1 0.9 
16 t018 1 0.9 
17 t084 1 0.9 
18 t085 1 0.9 
19 t1094 1 0.9 
20 t121 1 0.9 
21 t1247 1 0.9 
22 t127 1 0.9 
23 t314 1 0.9 
24 t318 1 0.9 
25 t359 1 0.9 
26 t541 1 0.9 
27 t605 1 0.9 
28 t648 1 0.9 
29 t932 1 0.9 
30 (*)?1 1 0.9 
31 err2 4 3.6 
 
Total 112 100.0 
1(*)?: This spa-type was not identified on the spa database website; (http://spatyper.fortinbras.us/). 
2: 4 isolates out of 112 were non-typeable by spa typing. 
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There was a wide range of clonal varieties, with twelve MLST clonal complexes (CCs) 
were identified. This was done with regard to the BURP analysis. The 12 identified 
MLST-CCs were: CC22, CC1, CC8, CC80, CC8/239, CC30, CC5, CC913, CC6, CC121, 
CC126 and CC15. Unfortunately, ten isolates (8.9%) were not found using the BURP 
analysis.  
 
The CC22 (17, 15.2%), CC1 (15, 13.4%), CC8 (15, 13.4%) and CC80 (15, 13.4%) were  
the predominant clones in this study, followed by CC8/239 (10, 8.9%), CC30 (9, 8.0%), 
CC5 (9, 8.0%), CC913 (6, 5.4%), CC6 (3, 2.7%), CC121 (1, 0.9%), CC126 (1, 0.9%) and 
CC15 (1, 0.9%) as represented in figure 4.15. 
 
 
 
Figure 4.15: All the MLST-CCs found in this study by the BURP analysis. 
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Here, the 12 found MLST-CCs were distributed among the identified spa types as shown 
in table 4.5.Whereas; a single clonal complex could contain more than one spa type. 
All of the four spa types: t223 (11, 9.8%), t1516 (4, 3.6%), t005 (1, 0.9%) and t541 (1, 
0.9%) were belonged to CC22 (17, 15.2%). The spa types t386 (14, 12.5%) and t127 (1, 
0.9) were belonged to the CC1 (15, 13.4%). For the CC8, it was found in 15 isolates also 
(13.4%), distributed as the following: t008 (12, 10.7%), t121 (1, 0.9%), t359 (1, 0.9%) 
and t648 (1, 0.9%). 
 
The spa types: t044 (12, 10.7%) and t131 (3, 2.7%) belonged to CC80 (15, 13.4%). The 
spa type t037 was found to be related either to CC8 or CC239 by the BURP and 
accounted for ten isolates (10, 8.9%). 
 
Also, the spa types: t021 (7, 6.3%), t018 (1, 0.9%) and t318 (1, 0.9%) belonged to CC30 
(9, 8.0%). The spa types: t002 (4, 3.6%), t688 (3, 2.7%) and t104 (2, 1.8%) belonged to 
CC5 in 9 isolates (8.0%). For the spa type t991, it was belonged to CC913 and accounted 
for six isolates (5.4%). The spa type t304 (3, 2.7%) belonged to CC6. For spa types: t314, 
t605 and t084, they were belonged to CC121, CC126 and CC 15, respectively. Each of 
these was accounted for 1 isolate in its CC (0.9%). 
 
Finally, the CCs using the BURP for the following spa types: t011, t085, t1094, t1247 
and t329 were not found, (Table 4.5). 
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Table 4.5: The MLST-CCs and the related spa types found in this study by the BURP. 
 
# MLST-CC1s spa types  no. of isolates (%) 
1 CC22 
t223 11(9.8%) 
t1516 4 (3.6%) 
t005 1 (0.9%) 
t541  1 (0.9%) 
2 CC1 
t386 14 (12.5%) 
t127 1 (0.9%) 
3 CC8 
t008 12 (10.7%) 
t121 1 (0.9%) 
t359 1 (0.9%) 
t648 1 (0.9%) 
4 CC80 
t044 12 (10.7%) 
t131 3 (2.7%) 
5 CC8/2392 t037 10 (8.9%) 
6 CC30 
t021 7 (6.3%) 
t018 1 (0.9%) 
t318 1 (0.9%) 
7 CC5 
t002 4 (3.6%) 
t688 3 (2.7%) 
t104 2 (1.8%) 
8 CC913 t991 6 (5.4%) 
9 CC6 t304 3 (2.7%) 
10 CC121 t314 1 (0.9%) 
11 CC126 t605 1 (0.9%) 
12 CC15 t084 1 (0.9%) 
13 NF3 
t011 1 (0.9%) 
t085 1 (0.9%) 
t1094 1 (0.9%) 
t1247 1 (0.9%) 
t932 1 (0.9%) 
(*)? 1 (0.9%) 
1: Clonal Complexes. 
2: The spa-t037 found to be CC8 or CC239 by the BURP, MLST is recommended for finite identification. 
3: Not Found by BURP. 
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The antimicrobial resistance rates among the MRSA spa types were studied. The 
resistance rates of MRSA isolates against erythromycin, were significantly high in the 
spa type t386 (p<0.005), followed by the spa types: t008 (8.9%), t044 (5.4%), t021 
(5.4%) and t223 (4.5%). Similarly, the resistance rates of MRSA isolates against 
clindamycin were high in the spa types: t386 (7.1%) and t008 (4.5%), followed by t044 
(3.6%) and t021 (2.7%), but with no statistically significance difference.  
 
Moreover, the resistance rates of MRSA isolates against ciprofloxacin and gentamicin 
were found significantly high (p<0.05) in the spa type t037 (7.1% for each). Also, for the 
spa types t008 and t044, they have a significant high resistance rate to ciprofloxacin 
(p<0.05). 
 
The MDR MRSA strains were distributed among 16 spa types. The rate of MDR (32, 
28.6%) were high in 8 isolates of spa types t008 and t044 (4 isolates in each) and in 6 
isolates of spa types t1516 and t037, (3 isolates in each). Two isolates in each of the 
following spa types: t002, t223, t386 were MDR, followed by one isolates for each of the 
spa types: t005, t021, t318, t359, t541, t648, t688, t932 and t991. Moreover, the spa (*) 
isolate and two of the spa (err) isolates were MDR. None of the following spa types: 
t011, t018, t084, t085, t104, t1094, t121, t1247, t127, t131, t304, t314, t648 were MDR 
strains. 
 
 Regarding the CCs, the highest MDR isolates were found among CC22 (7/32), followed 
by 6 isolates related to the CC8, 4 to CC80, 3 to CC5, 3 to CC8/239, 2 to CC1, 2 to CC30 
and 1 to CC913. Four MDR isolates CC’s were not found by the BURP, (Appendix; table 
4, page 102). 
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4.4.3 Phylogenetic analyses of the spa gene 
The genetic diversity between MRSA isolates and the phylogenetic relationships in the 
spa repeat region were studied.  
A high genetic diversity among MRSA isolates was noted. Phylogenetic analyses were 
conducted using the neighbor-joining, maximum-likelihood and maximum-parsimony. 
Based on spa typing repeats, the isolates were clustered into two main genotype groups, 
designated A and B. 
Group A consists of 45 MRSA isolates including 10 spa types: t688, t127, t131, t1247, 
t011, t1516, t037, t648, t386, t991 and the spa (*) isolate. Within this group, the isolates 
were clustered into two clades (clade A1 and clade A2). Within each clade, the spa types 
were sub-divided into two sub-clades (A1a, A1b, A2a and A2b).   
Clade A1 consists of 25 MRSA isolates out of 45 isolates with 8 spa types. The isolates 
of the spa types: t688, t127, t131, t1247 t011 and t1516 belonged to sub-clade A1a, while 
both the spa types t037 and t648 belonged to sub-clade A1b. Notably, the isolate of the 
spa typing (*) was also belonged to sub-clade A1b.  
Clade A2 consists of 20 MRSA isolates out of 45 isolates having three repeats. This clade 
was subdivided into two sub-clades (A2a and A2b). Interestingly, the spa type t386 
(r07:r23:r13) belonged to sub-clade A2a and the spa type t991 (r07:r33:r23) belonged to 
sub-clade A2b. 
Group B consists of 60 MRSA isolates, including 16 spa types, as the following: t314, 
t104, t044, t359, t002, t1094, t084, t085, t008, t304, t121, t005, t223, t021, t318, and 
t018. Within this group, the isolates were clustered into two clades (clade B1 and clade 
B2). Within each clade, the spa types were also sub-divided into two sub-clades (B1a, 
B1b, B2a and B2b). 
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Clade B1 consists of 16 MRSA isolates out of 60 isolates with 4 spa types. The isolates 
of the spa types t314 and t104 were belonged to the sub-clade B1a, while the spa types 
t044 and t359 were belonged to the sub-clade B1b.  
Clade B2 consists of 44 MRSA isolates out of 60 isolates with 12 spa types. Most 
isolates in clade B2 belonged to sub-clade B2a. Notably, these isolates with spa types 
with more than 8 repeats were clustered into this sub-clade. The isolates of the spa types: 
t002, t1094, t084, t085, t008, 1304, t121, t005 and t223 belonged to the sub-clade B2a, 
while the spa types: t021, t318 and t018 belonged to sub-clade B2b with more than 8 
repeats. The branching diagram of MRSA strains based on the spa genes is shown in 
Figure 4.16. 
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Figure 4.16: A Scheme represents the tree phylogram and the interrelationship between the sequencing derived from the spa 
sequencing and their correlation repeat sequences found through the spa typing.
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4.4.4 Toxin genes profiling: 
4.4.4.1 Detection of PVL toxin: 
Of all 112 MRSA isolates, thirty three (29.5%) were positive for PVL toxin gene. The 
size of the amplified DNA fragments for the PVL toxin gene was around (~433 bp), as 
shown in figure 4.17. 
 
 
Figure 4.17:  A representative agarose gel electrophoresis for the PVL toxin gene. Lanes 
1-3, 5-6: PVL positive. Lanes 4, 7-8 &10: PVL negative. Lane 9: positive control. Lane 
11: negative control. M: 100 bp DNA molecular weight marker. Band size is around 
~433bp. 
 
All the PVL positive MRSA isolates belonged to SCCmec type IV. Notably, 34% of the 
identified SCCmec type IV were PVL positive (33/97 type IV). PVL toxin gene was not 
found nor identified in isolates with SCCmec type I or V or the SCCmec NT isolates, as 
shown in table 4.6. 
 
 
  1         2         3       4          5        6         7        8         9         10      11      M      
100 bp 
500 bp 
300 bp 
200 bp 
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Table 4.6: PVL positive isolates and their SCCmec types as found in this study. 
PVL & SCCmec 
PVL 
Total Pos Neg 
SCCmec 
Type IV 33 64 97 
Type I 0 10 10 
Type V 0 1 1 
NT1 0 4 4 
Total 33 79 112 
1: non-typeable. 
 
 
Panton-Valentine Leukocidin (PVL) toxin gene was detected in eleven spa types: t044, 
t008, t223, t021, t002, t131, t104, t084, t121, t318 and t386.  
Two spa types: t044 and t008 were predominant and represent (11/12 t044, CC80: PVL 
+) and (10/12 t008, CC8: PVL +) isolates, respectively, and were associated with 
SCCmec type IV. 
 
Out of 11 isolates of the spa type t223, only one isolate was positive for the PVL toxin 
gene (1/11 t223, CC22: PVL +). Also, among 7 isolates with the spa type t021, only one 
isolate carried the PVL toxin gene (1/7 t021, CC30: PVL+). The two isolates with the spa 
type t002 found in this study were PVL toxin gene positive (2/2 t002, CC5: PVL+). 
 
All th isolates with the spa type t131 were PVL positive (3/3 t131, CC80: PVL+). 
Notably, all the isolates with the spa type t386 were PVL negative, except one t386 
isolate, which harbored the PVL toxin gene (1/14 t386, CC1: PVL +). 
All the other spa types, except the mentioned above, were PVL negative, (Table 4.7).  
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Table 4.7: The distribution of the PVL positive and negative isolates among their spa 
types and CCs as found in this study. 
PVL & spa types 
PVL 
Total 
Pos Neg 
spa types 
t044 (CC80) 11 1 12 
t008 (CC8) 10 2 12 
t223(CC22) 1 10 11 
t021 (CC30) 1 6 7 
t002 (CC5) 2 2 4 
t131 (CC80) 3 0 3 
t104 (CC5) 1 1 2 
t084 (CC15) 1 0 1 
t121 (CC8) 1 0 1 
t318 (CC30) 1 0 1 
t386 (CC1) 1 13 14 
Others1 0 44 44 
  Total 33 79 112 
1: Others: t005, t011, t018, 037, t085, t1094, t1247, t127, t1516, t304, t314, t359, t541, t605, t648, t688, 
t932 and t991. These spa types found to be PVL negative in this study. 
 
Combining all CCs with the 33 PVL-positive isolates, seven different clonal complexes 
were identified: CC80, CC8, CC5, CC30, CC22, CC15 and CC1. The most common 
were CC80 (14/33, 42.5%) and CC8 (11/33, 33.3%) followed by CC5 (3/33, 9.1%) and 
CC30 (2/33, 6.1%). Three PVL positive isolates were related to the CC22 (3.0%), CC15 
(3.0%) and CC1 (3.0%), (Figure 4.18). 
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Figure 4.18: The distribution of the PVL positive isolates among their CCs. 
 
4.4.4.2: Detection of ACME-arcA toxin gene: 
The gene coding for the ACME-arcA toxin was detected in 18.8 % (21/112) of isolates. 
The size of the amplified DNA fragments for the ACME-arcA toxin gene was around 
(~724 bp), as shown in figure 4.19. 
 
 
Figure 4.19: A representative agarose gel electrophoresis for the ACME-arcA toxin 
gene. Lanes 1-5 and 7-8: ACME-arcA positive. Lanes 6, 9-11: ACME-arcA negative. 
Lane 12: negative control. Lane 13: positive control. M: 100 bp DNA molecular weight 
marker.  
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The ACME-arcA toxin was detected in 20 isolates harboring the SCCmec type IV, and 1 
isolate with SCCmec type I. 
Arginine Catabolic Mobile Element (ACME)-arcA gene was detected in nine spa types: 
t008, t991 t037, t104, t1094, t1247, t1516, t223 and t386. This toxin was significantly 
predominant in the spa types t008 (p<0.05). Whereas, out of the 12 identified spa type 
t008, nine isolates were ACME-arcA positive (9/12 t008, CC8: ACME-arcA +), showing 
that this spa type is mostly ACME-arcA positive. These nine isolate were also PVL 
positive and classified as: USA-300 clone. Interestingly, out of the four non-typeable spa 
types (err), three were ACME-arcA toxin gene positive. 
Out of 10 isolates with the spa type t037, only one isolate harbored the ACME-arcA 
toxin gene (1/10 t037, CC8 or CC239: ACME-arcA +). The  same for the spa types t223 
and t386 in which only one isolate in each of these spa types was carrying the ACME-
arcA toxin gene, as follows: (1/11 t223, CC22: ACME-arcA +) and (1/14 t386, CC1: 
ACME-arcA +), respectively. 
Regarding the CCs, out of the 21 ACME-arcA positive isolates, six different clonal 
complexes were identified. The most common were CC8 (9/21), followed by: two 
isolates related to the CC913 (spa type t991), two isolates CC2 (t1516 and t223) and one 
isolate in each of the following CCs: CC8/CC239 (spa type t037), CC5 (spa type t104) 
and CC1 (spa type t386). Five ACME-arcA positive isolates CCs were not found, (Table 
4.8). 
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Table 4.8: The distribution of the ACME-arcA positive and negative isolates among 
their spa types and CCs as found in this study. 
ACME-arcA & spa types (CC) 
ACME-arcA Total 
Pos Neg 
spa types 
t008 (CC8) 9 3 12 
err1 (NF)2 3 1 4 
t991 (CC913) 2 4 6 
t037(CC8 or CC239) 1 9 10 
t104 (CC5) 1 1 2 
t1094 (NF) 1 0 1 
t1247 (NF) 1 0 1 
t1516 (CC2) 1 3 4 
t223(CC22) 1 10 11 
t386 (CC1) 1 13 14 
Others3 0 47 47 
 Total 21 91 112 
1: err are the non-typeable isolates by spa typing. 
2: CCs were not found using the BURP. 
3: Others: t002,t005, t011, 1018, t021, t044, t084, t085, t121, t127, t131, t304, t314, t359, t318, t541, t605, 
t648, t688 & t932.These spa types found to be arcA negative in this study. 
 
 
 
4.4.4.3 Detection of TSST-1 gene 
Similarly, 23% of the MRSA isolates (26/112) tested positive for the presence of the 
TSST-1 gene. The size of the amplified DNA fragments for the TSST-1 gene was around 
(~350 bp), as shown in figure 4.20. 
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Figure 4.20: A representative agarose gel electrophoresis for the TSST-1 gene. Lanes 1-
8: TSST-1 positive. Lane 9: positive control. Lanes 10-12: TSST-1 negative.  Lane 13: 
negative control. M: 1Kb DNA molecular weight marker. Band size is around ~350bp. 
 
Among the 26 positive TSST-1 gene, 25 MRSA isolates were belonged to the SCCmec 
type IV; the other TSST-1 positive isolate was belonged to SCCmec type I. 
Toxic shock syndrome toxin-1 (TSST-1) was detected in ten spa types: t223, t021, t1516, 
t002, 1005, t008, t018, t386, t541 and t605.  The two most common spa types among 
TSST-1 positive isolates were the spa type t223 and t021. Out of the 11 identified spa 
type t223, nine isolates were significantly TSST-1 positive (9/11 t223, CC22: TSST-1 +), 
showing that this spa type is mostly TSST-1 positive (p<0.05).  
 
All the seven spa type t021 isolates were TSST-1 positive (100%), as shown in table 4.9. 
TSST-1 gene was not detected among the other spa types found in this study. Notably, all 
the isolates of the spa type t044 (n=12), t037 (n=10), and t991 (n=6) were TSST-1 
negative.  
Also, this toxin was not predominant and found rarely in the spa types t008 and t386 in 
which it was found in only one isolate in each of t008 (1/12 t008, CC8: TSST-1 +) and  
t386 (1/14 t386, CC1: TSST-1 +) isolates. 
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Notably, genes for both PVL and TSST-1 together were observed only in one isolate 
belonged to spa type t021 (1/7 t021, CC30: PVL & TSST-1 +). 
 
Regarding the CCs, the TSST-1 positive isolates were detected predominantly in CC22 
(14/26, 53.8%) and CC30 (8/26, 30.8%). The other positive isolates were belonged to one 
isolates in each of the following CCs: CC126, CC8, CC5 and CC1.  
Table 4.9: The distribution of the TSST-1 positive and negative isolates among their spa 
types and CCs as found in this study. 
TSST-1& spa types (CC) 
TSST-1 
Total 
Pos Neg 
spa types 
t223 (CC22) 9 2 11 
t021 (CC30) 7 0 7 
t1516 (CC22) 3 1 4 
t002 (CC5) 1 3 4 
t005(CC22) 1 0 1 
t008 (CC8) 1 11 12 
t018 (CC30) 1 0 1 
t386(CC1) 1 13 14 
t541(CC22) 1 0 1 
t605 (CC126) 1 0 1 
Others1 0 56 1 
   Total 26 86 112 
1: Others: t011, t037, t044, t084, t085, t104, t1094, t121, t1247, t127, t131, t304, t314, t318, t359, t648, 
t688, t991 and t932. These spa types found to be TSST-1 negative in this study. 
 
 
 
 
4.4.4.4 Detection of ETA 
 
The gene coding for the exofoliative toxin A (ETA) was detected in 5.4 % (6/112) of all 
the MRSA isolates harboring the spa type t991/CC913. All the other spa types were ETA 
gene negative. The size of the amplified DNA fragments for the ETA gene was around 
(~93 bp), as shown in figure 4.20. 
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Among the 6 spa type t991, five isolates were of SCCmec type IV, and one isolate was 
belonged to SCCmec type I. None of the spa t991 ETA positive isolates were harboring 
the PVL or TSST-1 genes, and only one isolate was ACME-arcA toxin positive. 
 
 
Figure 4.21: A representative agarose gel electrophoresis for the ETA gene. Lane ETA 
negative. Lanes 2-4: ETA positive (spa type t991/CC913). Lane 4: negative control. M: 
1Kb DNA molecular weight marker. Band size was around ~93bp. 
 
4.5 Major MRSA clones in this study: 
Spa type t386: 
This spa type was the most predominant type among the all isolates (14, 12.5%) and 
belonged to CC1. 
Out of these fourteen t386 MRSA isolates, twelve isolates were significantly (p<0.05) 
negative for all the four toxin genes: PVL, TSST-1, ACME-arcA and ETA toxins. One of 
the other two isolates was negative for TSST-1, ACME-arcA and ETA toxins but positive 
for PVL toxin gene, and the second isolate was positive for both TSST-1 and ACME-
arcA but negative for PVL and ETA genes.  
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All the t386 MRSA isolates belonged to the SCCmec type IV. This spa type was found in 
Nablus (5/14), Jerusalem (3), Bethlehem (2), Hebron (2), Ramallah (1) and Tulkarem (1). 
Notably, this spa type was completely absent among isolates obtained from Gaza 
patients. 
Samples were collected mainly from adult males and from different sources. Among the 
14 isolates, two were assigned to MDR. All collected samples in t386 MRSA isolates 
were significantly (p<0.05) erythromycin resistant (14/14 t386, 100%). Eight isolates 
were clindamycin resistant (8/14 t386, 57.1%), three isolates were gentamicin resistant 
(3/14 t386, 21.4%) and three isolates were ciprofloxacin resistant (3/14 t386, 21.4%).  
Interestingly, all isolates in this spa type were sensitive to SXT, (Table 4.10). 
Table 4.10: Genotypic and phenotypic characteristics of spa type t386 as found in this 
study. 
 
1:  Patient type, 2: Male, 3: Not Found, 4: Female 
spa type t386/ CC1 (n=14) 
 
SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
Type IV 
 
neg neg neg Adult In M2 Neurosurgery Wound  
2 neg neg neg NF3 NF NF NF Wound 
3 neg neg neg Adult Out M Surgery Wound  
4 neg neg neg Adult In M NF Blood  
5 neg neg neg Adult In F4 NF Blood 
6 neg neg neg Adolescent In NF NF Ear 
7 neg neg neg NF NF NF NF Ear  
8 neg neg neg Adult Out M Dialysis Urine 
9 neg neg neg Adult In M ICU NF 
10 neg neg neg NF NF NF NF NF 
11 neg neg neg Adult In M Orthopedic NF 
12 neg neg neg Adult NF F NF Sputum 
13 pos neg neg NF Out M NF Sputum 
14 
 
neg pos pos Adult In M Daycare Pus 
MDR (2/14 t386); 100% erythromycin R, 57.1% clindamycin R, 21.4% gentamicin R, 
21.4% ciprofloxacin R, 100% SXT S. 
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Spa type t008: 
 
This spa type was predominant among 12 MRSA isolates (10.7 %) and belonged to CC8. 
Among the twelve t008 isolates, nine MRSA isolates were identified as: USA-300 clone 
(8% of all isolates), which were SCCmec IV and carrying both the PVL and the ACME-
arcA toxin genes (9/12, 75.0% of the spa type t008: USA-300).  
Two t008 isolates were SCCmec type IV but one was PVL positive and ACME-arcA 
negative. The other one was both PVL and ACME-arcA negative.  One isolate in this spa 
type harbored the SCCmec type I. For TSST-1, mostly all isolates were TSST-1 negative, 
except one isolate which was harboring the TSST-1 gene. 
This spa type was mostly isolated from five swabs of wound infections. For the patient 
type, 6 isolates were obtained from in-patients, 5 isolates from out-patients and one 
isolate with no data. The spa type t008 was predominant in Jerusalem (7/12) followed by 
Ramallah (4) and Nablus (1). Interestingly, it was not found among the isolates obtained 
from Gaza patients. 
Out of twelve isolates, four t008 isolates were MRSA MDR. Erythromycin resistance 
were observed in ten isolates (10/12 t008, 83.3%) with a statistically significant 
resistance rate (p<0.05). Clindamycin resistance was detected in five isolates (5/12, 
41.7%), and ciprofloxacin resistance was detected in nine isolates (9/12, 75%) with no 
statistically significance resistance rate for clindamycin (p>0.05), but significance 
resistance rate to ciprofloxacin (p<0.05). Notably, one t008 MRSA isolate was resistant 
to SXT (1/12, 8.0%), while all isolates in this spa type were significantly gentamicin 
sensitive (p<0.005), (Table 4.11).   
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Table 4.11: Genotypic and phenotypic characteristics of spa type t008 as found in this 
study. 
spa type t008/ CC8  (n=12) 
# SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
Type IV 
pos neg pos Adolescent In M2 Orthopedic Wound 
2 pos neg pos Adolescent Out M Orthopedic Wound 
3 pos neg pos Adolescent In M Orthopedic Wound 
4 pos neg pos Adult In M Orthopedic Wound 
5 pos neg pos Adult Out F3 Emergency Wound 
6 pos neg pos Adult Out F Emergency Abscess 
7 pos neg pos Adult Out M NF4 Pus 
8 pos neg pos Adult In F Surgery Skin 
9 pos neg pos NF NF NF NF NF 
10 pos neg neg Adult In M NF Blood 
11 neg pos neg Adult In F Neurosurgery Sputum 
12 Type I neg neg neg Adult Out F Daycare Urine 
MDR (4/12 t008); 83.3% erythromycin R,41.7% clindamycin R, 75.0% ciprofloxacin R, 
8.0% SXT R and 100% gentamicin S. 
1: Patient type, 2: Male, 3: Female, 4: Not Found. 
*: The bold and underlined # (1-9) are the USA-300 clone. 
 
Spa type t044: 
This spa type was common as the spa type t008, in which both were found in 12 MRSA 
isolates (10.7%). The spa type t044 has been found to be related to CC80. 
Eleven t044 MRSA isolates (11/12, 91.7%) were PVL positive showing a high 
significance association between the spa type t044 and harboring the PVL toxin gene 
(p<0.001), as expected in all other studies. A single isolate was negative for the PVL 
toxin gene, which was confirmed in duplicate. All t044 MRSA isolates were SCCmec 
type IV and were all significantly (p<0.001) negative for the TSST-1, ACME-arcA and 
ETA genes. 
Two isolates were obtained from 2 infants, while the others were obtained from 
adolescent and adults. Notably, PVL positive MRSA isolates were mostly isolated from 
67 
 
wound (6 isolates). For the patient type, most isolates (9/12) were obtained from in-
patients, while 3 isolates were obtained from out-patients. This spa type were observed 
commonly (p<0.05) in Gaza (7/11) followed by Jerusalem (4) and Hebron (1). 
Four t044isolateswere MRSA MDR. Half of these isolates were erythromycin resistant 
(6/12, 50.0%). Also, ciprofloxacin resistant (41.7%) was relatively common in this spa 
type. About one third (33.3%) were clindamycin resistant, while gentamicin and SXT 
resistance (2/12 t044, 16.7% for each) were relatively low, (Table 4.12).   
Table 4.12: Genotypic and phenotypic characteristics of spa type t044 as found in this 
study. 
spa type t044/ CC80 (n=12) 
# SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
Type IV 
 
 
pos 
 
neg 
 
neg 
 
Adult In M2 Neurosurgery Wound  
2 Adult In M Neuro ICU Wound  
3 Adult In M Orthopedic Wound  
4 Adolescent In M Orthopedic Wound  
5 Adult Out F3 Emergency Wound  
6 Adult Out F Emergency Wound 
7 Adult Out M Emergency Abscess 
8 Adult In M Daycare Abscess 
9 Adult In M ICU Blood 
10 Infant In F ICU Trap 
11 Adult In F Daycare Tissue 
12 neg Infant In F Pediatric Nasal  
MDR (4/12 t044); 50.0% erythromycin R, 33.3% clindamycin R, 41.7% ciprofloxacin 
R, 16.7% SXT R and 16.7% gentamicin R. 
1: Patient type, 2: Male, 3: Female. 
 
Spa type t223: 
Eleven patients (9.8% of all isolates) were infected by MRSA isolates belonging to this 
spa type, which was commonly typed, previously, as Gaza clone in Gaza region. 
Interestingly, six patients were from Gaza and five patients were from Jerusalem. The spa 
type t223 has been found to be related to CC22. 
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This spa type is usually PVL negative. Here, most isolates (10/11 t223) were 
significantly PVL toxin gene negative (p<0.001). One isolate was PVL toxin gene 
positive and was tested in duplicate and confirmed blindly in laboratories of Sheba 
Medical Center, Tel-Hashomer, Israel. However, the spa type t223 with PVL positive 
toxin gene was considered as a “Unique Gaza strain”.  
All isolates were significantly positive for the TSST-1 gene (p<0.001) except two isolates 
which were negative for this toxin and tested in duplicates. In contrary, all isolates were 
significantly negative for ACME-arcA toxin gene except one isolate (p<0.005) that was 
also positive for the PVL toxin gene (1/11 t223: PVL/ACME-arcA +, TSST-1 –) and 
considered as “Unique Gaza Strain”. All isolates in this spa type were SCCmec type IV. 
Most of the isolates (9/11 t223) were obtained from in-patients, while one isolate was 
obtained from an out-patient and one isolate with no data. 
Two t223 isolates were MRSA MDR. Erythromycin resistance was relatively common 
(5/11 t223, 45.5%) and significant among t223 isolates (p<0.005). Two isolates were 
clindamycin resistant (2/11 t223, 18.2%), three isolates were SXT resistant (3/11 t223, 
27.3%), two isolates were gentamicin resistant (2/11 t233, 18.2%) and only one isolate 
(1/11 t223, 9.1%) was ciprofloxacin resistant, (Table 4.13).  
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Table 4.13: Genotypic and phenotypic characteristics of spa type t044 as found in this 
study. 
spa type t223/ CC22 (n=11)  -Gaza clone- 
# SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
 
Type IV 
 
neg 
 
 
pos 
neg 
 
 
Child In M2 Pediatric Blood 
2 pos Adult In F3 ICU Blood  
3 pos Adult In M Neurosurgery Nasal  
4 pos Adolescent In M Surgery Nasal  
5 pos Adult In M Medical 
 
Nasal 
6 neg Adult Out F Orthopedic Pus 
7 pos Adolescent In M Surgery Urine 
8 pos Adult In M Neuro-ICU NF4 
9 pos Adult In M CCU NF 
10 pos NF NF NF NF NF 
11* pos neg pos Adolescent In M Orthopedic Wound  
MDR (2/11 t233); 45.5% erythromycin R,18.2% clindamycin R, 9.1% ciprofloxacin R, 
27.3% SXT R and 18.2% gentamicin R. 
1: Patient type, 2: Male, 3: Female, 4: Not Found. 
*: This isolate is considered as a “Unique Gaza Strain”. 
spa type t037: 
Ten patients (8.9%) were infected with isolates belonged to the spa type t037. This spa 
type is belonged to CC8 or CC239 by the BURP. For complete identification, MLST is 
recommended. 
All t037 MRSA isolates were significantly negative for PVL, TSST-1, ACME-arcA and 
ETA genes (p<0.005), except one isolate which was ACME-arcA toxin gene positive.  
Six isolates were SCCmec type IV and 2 isolates were belonged to SCCmec type I. Two 
t037 isolates were non-typeable by both individual and multiplex PCR for the five 
examined SCCmec types I-V. 
Mostly, this spa type was detected among hospitalized (in patients) patients from Gaza 
(n=5), Nablus (n=2), Jerusalem (n=1) and Ramallah (n=1).Three isolates were MRSA 
MDR. Four isolates were erythromycin resistant (4/10, 40.0%) and two isolates were 
clindamycin resistant (2/10, 20.0%). Notably, this spa type has high significant resistance 
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rates (p<0.05) to both ciprofloxacin and gentamicin (80.0%). Moreover, one t037 isolate 
was SXT resistant (1/10, 10%), (Table 4.14). 
Table 4.14: Genotypic and phenotypic characteristics of spa type t037 as found in this 
study 
spa type t037/ CC8-CC239  (n=10) 
# SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
 
Type IV 
 
 
 
neg 
 
 
 
neg 
 
 
pos Adult In M2 Neurosurgery NF4 
2  
neg 
 
 
 
NF Out F3 Daycare Urine 
3 Adult In M Neurosurgery Pus 
4 NF NF NF NF Nasal  
5 Adult In F Gynecology Wound 
6 Adult In M Orthopedic Wound 
7 Type I NF NF NF NF Tissue 
8 Type I Infant In M Pediatric Blood 
9 NT5 Adult In F Orthopedic Wound  
10 NT Adult In F Orthopedic Tissue  
MDR (3/10  t037); 40.0% erythromycin R,20.0% clindamycin R, 80.0% ciprofloxacin 
80.0% gentamicin R and 10.0% SXT R. 
1: Patient type, 2: Male, 3: Female, 4: Not Found, 5: Non-typeable. 
 
spa type t021: 
This spa type was detected in 7 isolates (6.3%). The spa type t021 has been found to be 
related to CC30. 
All t021 isolates were significantly carrying the TSST-1 gene (p<0.001). In contrast, all 
were significantly negative for the ACME-arcA and ETA genes (p<0.005). Also, all were 
PVL toxin gene negative, but one isolate was harboring the PVL toxin gene. All isolates 
in this spa type were related the SCCmec type IV. 
Most isolates were carried among hospitalized patients, except one isolate which was 
obtained from an out-patient. All t021 isolates were obtained from males. Sources of 
these isolates were as the following: 4 isolates were obtained from wounds, two isolates 
from blood and 1 isolate was obtained from a nasal swab culture. Interestingly, this spa 
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type was predominant in Hebron (4/7), followed by Nablus (2) and Jerusalem (1). 
Notably, no t021 MRSA isolates were obtained from the patients from Gaza.  
One t021 MRSA isolate was MDR in which it was resistant to erythromycin, clindamycin 
and SXT (in addition to resistance to the β-lactam antibiotics), (Table 4.15). 
Table 4.15: Genotypic and phenotypic characteristics of spa type t021 as found in this 
study. 
spa type t021/ CC30  (n=7) 
# SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
Type IV 
 
pos 
 
 
pos 
 
 
 
 
neg 
 
Adolescent In M2 Surgery Wound  
2 
 
neg 
 
Adolescent Out M Emergency Wound  
3 Child In M Pediatric Wound 
4 Adult In M Orthopedic Wound 
5 Adolescent In M ICU Nasal  
6 Child In M Pediatric Blood  
7 Adult In M Medical ward Blood  
MDR (1/7 t021, 14.3%). 
1: Patient type, 2: Male. 
 
spa type t991: 
As described before, the spa type t991 was found in six isolates that were all significantly 
ETA positive, PVL negative and TSST-1 negative (p<0.001). For ACME-arcA, two 
isolates were positive, while the other 4 were negative. The spa type t991 has been found 
to be related to CC913. 
Among these six t991 MRSA isolates, two isolates were obtained from infants, one from 
child, one from adolescent and two from adults. Sources of these isolates were mainly 
wound (3 isolates), ear swab (1) and blood culture (1). One isolate source was not 
identified. For the patient type, five isolates were obtained from in-patients, while one 
isolate was obtained from an out-patient. This spa type was distributed equally between 
Gaza, Hebron and Ramallah with two isolates from each region. 
72 
 
 Only one MRSA isolate in this spa type was MDR in which it was resistant to 
erythromycin, clindamycin, SXT and ciprofloxacin in addition to resistance to the β-
lactam antibiotics, (Table 4.16). 
Table 4.16: Genotypic and phenotypic characteristics of spa type t991 as found in this 
study. 
spa type t991/ CC913 (n=6) 
# SCCmec PVL TSST-1 arcA Age group Pt-type1 Sex Department Source 
1 
 
Type IV 
 
neg 
 
neg 
 
pos Infant In F2 Pediatric NF4 
2 neg Child In F Pediatric Ear 
3 pos Adult Out F Dialysis Wound 
4 neg Infant In M3 Pediatric Blood 
5 neg Adolescent In M Daycare Wound 
6 Type I neg Adult In F Orthopedic Wound 
MDR (1/6 t991, 16.7%) 
1: Patient type, 2: Female, 3: Male, 4: Not Found. 
 
4.6 Other MRSA clones: 
In addition to the major MRSA clones that were described above, other clones were 
found to be related to the other 22 spa types. Table 4.17 summarizes the other found 
MRSA clones with their SCCmec types, spa types, toxin genes profiling and region from 
where they were isolated. The CCs for the spa types were found by BURP. In summary, 
the molecular and antibiogram items, the phenotypic and genotypic characteristics of all 
MRSA isolates included in this study are summarized in table 4.18. 
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Table 4.17: Genotypic and phenotypic characteristics of the other spa types as found in 
this study. 
# spa type 
SCCmec 
type (n) 
MLST-
CCs PVL TSST-1 arcA Region 
1 
t002 Type IV 4 CC5 
pos neg 
Neg 
Hebron 
2 pos neg Jerusalem 
3 neg pos Jerusalem 
4 neg neg Ramallah 
5 
t1516 Type IV 4 CC22 neg pos 
pos Jerusalem 
6 neg Ramallah 
7 neg Ramallah 
8 Type I neg neg Hebron 
9 t104 Type I 2 CC5 neg neg neg Gaza 10 Type IV pos neg pos Jerusalem 
11 
t131 Type IV 3 CC80 pos neg neg 
Gaza 
12 Hebron 
13 Hebron 
14 
t304 Type IV 3 CC6 neg neg neg 
Gaza 
15 Gaza 
16 Gaza 
17 
t688 
Type IV 
3 CC5 neg neg neg 
Jerusalem 
18 Type I Hebron 
19 Type I Gaza 
20 t648 
 
Type IV 
1 CC8 neg neg neg Gaza 
21 t359 1 CC8 neg neg neg Gaza 
22 t121 1 CC8 pos neg neg Nablus 
23 t005 1 CC22 neg pos neg Jerusalem 
24 t541 1 CC22 neg pos neg Gaza 
25 t084 1 CC15 pos neg neg Gaza 
26 t127 1 CC1 neg neg neg Jerusalem 
27 t318 1 CC30 pos neg neg Nablus 
28 t605 1 CC126 neg pos neg Jerusalem 
29 t1094 1 NF neg neg pos Jerusalem 
30 t1247 1 NF neg neg pos Jerusalem 
31 t011 1 NF neg neg neg Gaza 
32 t932 1 NF neg neg neg Hebron 
33 t085 Type I 1 NF neg neg neg Jerusalem 
34 t018 Type I 1 CC30 neg pos neg Ramallah 
35 t314 NT 1 CC121 neg neg neg Tubas 
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Table 4.18 The molecular and antibiogram items, the phenotypic and genotypic characteristics of all MRSA isolates included in 
this study 
Age group Spa spa repeat succession MLST-CC SCCmec PVL TSST-1 arc-A MDR Region 
Adult  t386 (9) r07:r23:r13 CC1 Type IV neg neg neg Y (2), N(7) 
Jerusalem(2),Nablus (2),Hebron (2), Bethlehem, 
Nablus, Ramallah 
n=68 t044 (9) r07:r23:r12:r34:r34:r33:r34 CC80 Type IV pos neg neg Y(4), N(5) Gaza (5), Jerusalem (4) 
  t008 (8) r11:r19:r12:r21:r17:r34:r24:r34:r22:r25 CC8 Type IV (7), Type I (1) 
pos  (6), neg 
(2) 
pos(1), neg 
(7) 
pos(5), neg 
(3) 
Y(2), N 
(6) Ramallah(4), Jerusalem(4) 
  t037 (6) r15:r12:r16:r02:r25:r17:r24 CC8/239 
Type IV (4), NT 
(2) neg neg 
pos(1),neg(5
) 
Y(1),N(5
) Gaza (5), Jerusalem 
  t223 (6) r26:r23:r13:r23:r05:r17:r25:r17:r25:r16:r28 CC22 Type IV neg pos(5), neg (1) neg 
Y(2), 
N(4) Gaza(3), Jerusalem(3) 
  t1516(3
) r26:r25:r17:r25:r16:r28 CC22 Type IV neg pos 
pos(1),neg(2
) 
Y(2), 
N(1) Bethlehem(2),Jerusalem 
  t002 (2) r26:r23:r17:r34:r17:r20:r17:r12:r17:r16 CC5 Type IV neg neg (1), pos (1) neg Y,N Ramallah (1), Jerusalem (1) 
  t131 (2) r07:r23:r12:r34:r33:r34 CC80 Type IV pos neg neg Y,N Hebron 
  t021 (2) r15:r12:r16:r02:r16:r02:r25:r17:r24 CC30 Type IV neg pos neg N Hebron 
  t991 (2) r07:r33:r23 CC913 Type I, Type IV neg neg neg, pos Y,N Ramallah 
  t688 (2) r26:r23:r17:r34:r17:r16 CC5 Type I, Type V neg neg neg N Gaza, Jerusalem 
  t011 r08:r16:r02:r25:r34:r24:r25 NF Type IV neg neg neg N Gaza 
  t304 r11:r10:r21:r17:r34:r24:r34:r22:r25 CC6 Type IV neg neg neg N Gaza 
  t005 r26:r23:r13:r23:r31:r05:r17:r25:r17:r25:r16:r28 CC22 Type IV neg pos neg Y Jerusalem 
  t018 r15:r12:r16:r02:r16:r02:r25:r17:r24:r24:r24 CC30 Type I neg pos neg N Ramallah 
  t084 r07:r23:r12:r34:r34:r12:r12:r23:r02:r12:r23 CC15 Type IV pos neg neg N Gaza 
  t085 r07:r23:r12:r34:r34:r12:r23:r02:r12:r23 NF Type I neg neg neg N Jerusalem 
  t104 r11:r10:r34:r22:r25 CC5 Type I neg neg neg N Gaza 
  t1094 r23:r17:r34:r17:r20:r17:r12:r17:r16 NF Type IV neg neg pos N Jerusalem 
  t121 r11:r19:r21:r17:r34:r24:r34:r22:r25 CC8 Type IV pos neg neg N Nablus 
  t1247 r07:r23:r34:r34:r33:r34 NF Type IV neg neg pos N Jerusalem 
  t127 r07:r23:r21:r16:r34:r33:r13 CC1 Type IV neg neg neg N Jerusalem 
  t359 r07:r23:r12:r21:r17:r34:r34:r33:r34 CC8 Type IV neg neg neg Y Gaza 
  t605 r07:r23:r13 CC126 Type IV neg pos neg N Jerusalem 
  t932 r12:r16:r02:r25:r17:r24 NF Type IV neg neg neg Y Hebron 
  (*)? __________ NF NT neg neg neg Y Gaza 
  Err __________ NF Type I neg neg pos Y Ramallah 
  Err __________ NF Type IV neg neg pos N Bethlehem 
Adolescen
t t008 (3) r11:r19:r12:r21:r17:r34:r24:r34:r22:r25 CC8 Type IV pos neg pos Y Jerusalem 
n=16 t021 (3) r15:r12:r16:r02:r16:r02:r25:r17:r24 CC30 Type IV pos (1), neg (2) pos neg N Nablus (2), Jerusalem 
  t223 (3) r26:r23:r13:r23:r05:r17:r25:r17:r25:r16:r28 CC22 Type IV pos (1), neg (2) 
pos (2), 
neg (1) 
pos (1), neg 
(2) N Gaza(2),Jerusalem 
  t304 (2) r11:r10:r21:r17:r34:r24:r34:r22:r25 CC6 Type IV neg neg neg N Gaza 
  t044 r07:r23:r12:r34:r34:r33:r34 CC80 Type IV pos neg neg N Gaza 
  t386 r07:r23:r13 CC1 Type IV neg neg neg N Bethlehem 
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  t648 r11:r21:r17:r34:r24:r34:r22:r25 CC8 Type IV neg neg neg Y Gaza 
  t314 r08:r17:r23:r18:r17 CC121 NT neg neg neg N Tubas 
  t991 r07:r33:r23 CC913 Type IV neg neg neg N Gaza 
Children  t021 (2) r15:r12:r16:r02:r16:r02:r25:r17:r24 CC30 Type IV neg pos neg Y,N Hebron 
n=8 t104 r11:r10:r34:r22:r25 CC5 Type IV pos neg pos N Jerusalem 
  t131 r07:r23:r12:r34:r33:r34 CC80 Type IV pos neg neg N Gaza 
  t1516 r26:r25:r17:r25:r16:r28 CC22 Type I neg neg neg Y Hebron 
  t223 r26:r23:r13:r23:r05:r17:r25:r17:r25:r16:r28 CC22 Type IV neg pos neg N Gaza 
  t541 r26:r17:r25:r17:r25:r16:r28 CC22 Type IV neg pos neg Y Gaza 
  t991 r07:r33:r23 CC913 Type IV neg neg neg N Hebron 
Infant  t991 (2) r07:r33:r23 CC913 Type IV neg neg pos N Gaza, Hebron 
n=10 t002 (2) r26:r23:r17:r34:r17:r20:r17:r12:r17:r16 CC5 Type IV pos neg neg Y,N Hebron, Jerusalem 
  t044 (2) r07:r23:r12:r34:r34:r33:r34 CC80 Type IV neg, pos neg neg N Gaza, Hebron 
  t037 r15:r12:r16:r02:r25:r17:r24 CC8/239 Type I neg neg neg N Gaza 
  t688 r26:r23:r17:r34:r17:r16 CC5 Type IV neg neg neg Y Hebron 
  err (2) __________ NF Type IV neg neg neg, pos Y,N Ramallah, Jerusalem 
NF  t386 (4) r07:r23:r13 CC1 Type IV neg(3), pos (1) neg neg N Nablus (3),Jerusalem 
n-10 t037 (3) r15:r12:r16:r02:r25:r17:r24 CC8/239 
Type IV (2), Type 
I neg neg neg Y (2), N Nablus (2), Ramallah 
  t008 r11:r19:r12:r21:r17:r34:r24:r34:r22:r25 CC8 Type IV pos neg pos N Nablus 
  t223 r26:r23:r13:r23:r05:r17:r25:r17:r25:r16:r28 CC22 Type IV neg pos neg N Jerusalem 
  t318 r15:r12:r16:r16:r02:r16:r02:r25:r17:r24 CC30 Type IV pos neg neg Y Nablus 
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Chapter Five: 
 
Discussion, Conclusions, Limitations and Recommendations 
 
 
 
5.1 Discussion 
MRSA is a major pathogen in hospitals and among healthy populations, characterized by 
different resistance mechanisms and associated with a broad variety of mild skin and soft 
tissue infections to serious life threatening and invasive diseases with severe morbidity 
and mortality rates (Cardona & Wilson, 2015; Gardam, 2000; Gordon & Lowy, 2008; 
Reddy, Srirama, & Dirisala, 2017; Simor, Loeb, & Committee, 2004; Stryjewski & 
Chambers, 2008). 
Our knowledge of the major MRSA types and clones in Palestine is not well established; 
most reports mainly describe the prevalence and the SCCmec types of MRSA among 
community and health care workers. This study aimed to investigate the epidemiological 
and genetic diversity of MRSA isolates in healthcare settings in Palestine, from 2015 to 
2017. 
 
This study was conducted over a period of 2 years (2015-2017) to characterize the 
molecular and the antimicrobial profile of MRSA isolates in Palestinian regions. Most 
isolates were obtained from Al- Makassed Islamic Charitable Society Hospital (68.8% of 
all isolates). Al-Makassed Islamic Charitable Society Hospital is one of the most 
important and leading medical institutions in Palestine. It is located in East Jerusalem and 
has been established since 1956. Al-Makassed Islamic Charitable Society Hospital 
currently has about 250 beds and a staff of 750 employees. This hospital provides 
medical services to all Palestinians in the West Bank, Gaza Strip and East Jerusalem. It is 
considered as a referral hospital, receiving patients from all over the nation in Palestine.   
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Here, the antibiogram and resistance rates to different antibiotics among MRSA isolates 
were investigated. In this study, it has been noticed that the resistance rate to 
erythromycin was high (63.4%) in comparison to other local and nearby countries 
studies. However, a study conducted in Palestine by Kaibni et al has shown a low 
resistance rate to erythromycin (18.5%) (Kaibni, Farraj, Adwan, & Essawi, 2009). 
Another study conducted in Gaza strip has reported a resistance rate of 37.9% to 
erythromycin (Biber et al., 2012). In a study conducted in Jordan, resistance rate to 
erythromycin was reported to be 42.8% (Aqel, Alzoubi, Vickers, Pichon, & Kearns, 
2015). Recently, in Egypt, MRSA resistance rate among to erythromycin was in a percent 
of 52.9% (Khairalla, Wasfi, & Ashour, 2017). Similarly, a high resistance rate to 
erythromycin (58.6%) was reported in Iran (Goudarzi et al., 2017). Higher resistance 
rates to erythromycin were reported in Israel and Germany (70.0%, 77.8%), respectively 
(Biber et al., 2015; Cuny et al., 2015). Interestingly, in a study conducted in the northern 
region of Palestine, a resistance rate to erythromycin was as high as 96% among MRSA 
isolates (Adwan et al., 2013). 
 
For clindamycin, 34.8% of our MRSA strains were resistant. That, similarly, agrees with 
a study conducted in Palestine in 2013 (52%) and in Iran (46.9%) (Adwan et al., 2013; 
Goudarzi et al., 2017). A notable higher clindamycin resistance rates (61.7%, 69.9%) 
were reported in Israel and Germany, respectively (Biber et al., 2015; Cuny et al., 2015). 
On the other hand, a lower MRSA clindamycin resistance rates were reported in Egypt 
(26.5%) and Jordan (5.35%) (Aqel et al., 2015; Khairalla et al., 2017). 
Regarding gentamicin, 23.2% of our MRSA isolates were resistant. Similarly, 20% of 
MRSA isolates were resistant to gentamicin in a study conducted in the Primary Hospital 
in Gaza (Al Laham et al., 2015). A higher gentamicin resistance rate was reported in the 
neighboring countries; such as: Israel (37.9%) (Biber et al., 2015) and Egypt (73.5%) 
(Khairalla et al., 2017). However a low resistance rate (3.5%) to gentamicin was reported 
in Germany (Cuny et al., 2015). Interestingly, no gentamicin resistant MRSA isolates 
were reported in a recent study conducted in Jordan (Aqel et al., 2015). 
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For trimethoprim-sulfamethoxazole, in the last few years, it has been known and reported 
that MRSA isolates are usually susceptible to this antibiotic in a percent of (97-99%) 
(Aguadero, Gonzalez-Velasco, Vindel, Gonzalez-Velasco, & Moreno, 2015; Berla-
Kerzhner et al., 2017; Biber et al., 2012; Biber et al., 2015; Cuny et al., 2015) 
Interestingly, in this study, most isolates were sensitive to SXT (81.3%), but 18.8% of 
MRSA isolates were SXT resistant. In a recent study conducted in India, SXT resistance 
rate among MRSA isolates was very similar to ours (18.9%) (Pramodhini, 2017). A study 
conducted in Gaza has shown a slightly higher resistance rate to SXT (20.0%) among 
MRSA isolates (Al Laham et al., 2015), while a study conducted in Germany/North 
Rhine has revealed that only 0.2% of 1952 MRSA isolates were SXT resistant (Cuny et 
al., 2015). Moreover, a high resistance rate to SXT (33.6%) was reported recently in Iran 
(Goudarzi et al., 2017). Also, a notable high SXT resistance rate (59.0%) was reported in 
Pakistan (Idrees, Jabeen, Khan, & Zafar, 2009). 
 For ciprofloxacin, resistance rate among our MRSA strains was (39.3%), which was in 
disagreement with a study conducted in Israel in 2015, where the resistance rate to 
ciprofloxacin was extremely high (83.9%) (Biber et al., 2015). Another much higher 
resistance rate to ciprofloxacin (95.9%) was reported in Germany (Cuny et al., 2015). A 
study conducted in 2003 on the CA-MRSA in Palestine revealed a resistance rate to 
ciprofloxacin of 29.6%, similar to our findings (Kaibni et al., 2009). Lower resistance 
rates to ciprofloxacin were reported in Jordan and Israel (3.5%, 0.3%), respectively (Aqel 
et al., 2015; Biber et al., 2012). These differences in the resistance rates among different 
countries could be due to the misuse and abuse of ciprofloxacin and other next 
generations of quinolones; such as levofloxacin (Fair & Tor, 2014). Also, it could be due 
the over prescription and selection pressure on this antibiotic for the treatment not only 
for MRSA infections, but also other infections caused by different bacterial strains, even 
gram negative organism since ciprofloxacin is a broad-spectrum synthetic antibiotic 
(King, Malone, & Lilley, 2000). However, ciprofloxacin resistance can develop rapidly 
and this may limit the usefulness of quinolones for treating MRSA in some destination 
(Blumberg, Rimland, Carroll, Terry, & Wachsmuth, 1991; Hershow, Khayr, & 
Schreckenberger, 1998).  
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According to the MDR definition proposed by Magiorako et al, MDR isolate is usually 
resistant to at least three different non β lactam antibiotic group in addition to be resistant 
to β-lactam antibiotics (i.e., penicillins and cephalosporins) (Magiorakos et al., 2012). In 
our study, 32 MRSA isolates were MDR (28.6%). In comparison with other MRSA MDR 
reports based on the same above definition, a high MDR resistance rate (60.0%) was 
reported in Israel (Biber et al., 2015), while a similar MDR resistance rate (25.0%) was 
reported in Jordan by Bazzoun et al (Bazzoun et al., 2014). However, no MDR strains 
(according to the same definition), were reported in a state wide surveillance of antibiotic 
resistance patterns study conducted on 1952 MRSA isolates in North Rhine-Westphalia 
(Cuny et al., 2015). 
This broad and diverse antimicrobial resistance patterns among MRSA isolates between 
different regions could be due to the different antibiotic regimens between countries and 
the selection pressure on certain antibiotics by the physicians. This diversity is an alarm 
to the crucial need to refer MRSA antimicrobial therapy to culture results which are the 
only ideal predictors for appropriate treatment approaches in which appropriate 
susceptibility reports are really necessary for optimum and lifesaving therapy of MRSA 
infections. 
In this study, highest susceptibility patterns were noticed among SXT (81.3%), 
gentamicin (76.8%) and ciprofloxacin (65.2%). This may aid medical laboratory 
technologist to test the susceptibility of these antibiotics to be used as therapeutic options 
for the treatment of MRSA infections. Also, as it has been found that no VRSA strains 
were reported in this study,  physicians can still prescribe this antibiotic based on 
empirical therapy when needed, especially for urgent infections, while lower 
susceptibility patterns were found among macrolides (erythromycin) and lincosamides 
(clindamycin). 
These findings support the need of antibiotic stewardship and wise antibiotic selection to 
eliminate any further development of more resistant MRSA strains; this may preserve the 
still effective antibiotics as valuable therapeutic resources, especially when we analyze 
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the molecular characteristics and the toxins carriage by the MRSA isolates that emerged 
in our country and elsewhere. 
Each strain was characterized by: staphylococcal chromosomal cassette mec (SCCmec), 
Staphylococcus aureus protein A (spa) and a panel of toxin genes, including: Panton-
Valentine Leukocidin (PVL), ACME-arcA, Toxic Shock Syndrome Toxin-1 (TSST-1) 
and Exfoliative Toxin A (ETA). The SCCmec type IV is the smallest structural type 
among the SCCmec types and is believed to be the most mobile version that is associated 
with CA-MRSA and having characteristic of some nosocomial MRSA clones of HA-
MRSA infections. This type is mainly associated with the CA-MRSA based on the 
molecular and genetic characteristic (Milheirico, Oliveira, & de Lencastre, 2007a; 
Robinson & Enright, 2003). However, the CA-MRSA clones are getting more implicated 
in nosocomial infections with increased colonization and transmissibility characteristics 
which may ultimately displace HA-MRSA clones (Otto, 2012). Currently, MRSA strains 
distinctions based on the hospitalization days and clinical epidemiology are beginning to 
blur and becoming less relevant and confusing as CA-MRSA is being transmitted in the 
health care related-setting. This disagreeing in favor of genotyping and molecular 
characterization of MRSA strains (Gonzalez et al., 2006; Mediavilla, Chen, Mathema, & 
Kreiswirth, 2012). 
Nowadays the accurate definition of the CA-MRSA and the HA-MRSA is problematic 
and confused based on the hospitalization days and the traditional risk factors 
eliminations, such as: recent hospitalization, residence in a long-term care facility or 
medical devices, history of MRSA carriage, dialysis, or surgery within the last year 
(Rachel J. Gorwitz, 2006). However, the CDC has defined the CA-MRSA either as an 
infection of an outpatient that has not been hospitalized or an infection that has been 
isolated before 72 hrs or within the first 48 hrs of hospitalization (David & Daum, 2010; 
David et al., 2008; Rachel J. Gorwitz, 2006). 
Thus, on the basis of the hospitalization days, not all the CA-MRSA are truly community 
infections and the molecular typing should be included for accurate definition for the type 
of MRSA infections, either CA-MRSA or HA-MRSA. 
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Interestingly, our findings were consistent with the previous studies showing the shift in 
MRSA strains among the Palestinian populations to be more community acquired 
(SCCmec types IV and V). However, many studies have shown shifts in MRSA strains to 
be community associated with new emerged clones among different populations. This 
shift of MRSA infections have been associated with the detection of new MRSA strains 
that are different from the previous HA-MRSA strains which can spread easily and 
rapidly among healthy people in the community that lack risk factors for exposure or 
contact to the health care system (Boswihi, Udo, & Al-Sweih, 2016; David & Daum, 
2010; Udo, Pearman, & Grubb, 1993).  
 
This study revealed that the predominant MRSA strains in our region are community 
acquired, with a high diversity among the MRSA clones which were harboring different 
toxins and virulence genes that are related to severity and infectivity of MRSA infections 
and can affect the response to the treatment approaches.  
 
Even though most isolates in this study were obtained from in-patients (67.9%), but the 
molecular analysis showed that most MRSA strains isolated from these in-patients are 
mostly community acquired, (type IV, 86.6%). This can give a good indication that we 
have a high carriage of MRSA among healthy population or the health care workers in 
our region. These MRSA isolates could be carried as a normal flora in skin, hands, and 
groin or in the nasal cavity of the health care workers or the patients themselves, but 
when these patients are hospitalized or have an opened wound or surgery, their immunity 
may fall down allowing this normal flora or colonization to cause secondary infections. 
Therefore, hand hygiene and infectious control programs must be applied well in our 
hospitals. So, the MRSA infection may be caused from the patients themselves as they 
were normally colonized with MRSA before hospitalization or from the visitors or the 
health care workers. This interface may serve as a causative agent of cross contamination 
of hospital acquired and community acquired MRSA infections.  
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Also, it has been reported that carriage of MRSA is a major risk factor for transmission 
and subsequent infections that may develop to systemic or severe infections (Kuehnert et 
al., 2006; Piechowicz, Garbacz, Wisniewska, & Dabrowska-Szponar, 2011). A recent 
study conducted at Al-Shifa hospital in Gaza Strip for the nasal carriage of MRSA has 
shown a carriage rate of MRSA among the health care workers equal to 25.5%. This 
highlights that there is a high carriage rate of MRSA among the Palestinian populations, 
especially the health care workers who are in contact with the vulnerable patient in the 
hospitals (El Aila, Al Laham, & Ayesh, 2017).  Moreover, a study conducted by Adwan 
and his colleagues has shown a nasal carriage rate of S. aureus of 24% among Palestinian 
students with 9% MRSA carriage (Adwan et al., 2013). 
 
Our results regarding the SCCmec typing and the shift to CA-MRSA infection (86.6% 
type IV) highly agree with a study done in Copenhagen (Bartels, Boye, Rhod Larsen, 
Skov, & Westh, 2007), where Bartels and his colleagues have reported that there is a 
rapid increase of genetically diverse strains with shift to CA-MRSA, where SCCmec type 
IV was found in (86% )of isolates.  
Moreover, in a large study about the epidemiology of MRSA in the southern-eastern 
Mediterranean countries, it has been shown that there is a significant presence of MRSA 
in Egypt, Jordan, Algeria, Malta, Morocco, Tunisia, Cyprus, Lebanon and Turkey. In this 
study, 62 hospitals were included showing an evidence of endemicity of MRSA in these 
regions (Borg et al., 2007). Also, it has been reported that there is an introduction of 
several MRSA strains with intercontinental exchange of new MRSA clones in the Middle 
East (Tokajian, 2014).  
 
In a recent study conducted in Gaza by Al Laham and his colleagues, similar results were 
obtained with a high frequency of the SCCmec type (type IV), which accounted for 
(79.3%) of MRSA isolates. This study has revealed that the most dominant spa types 
were t223 and t044. From seven isolates in this study with the spa type t223, one isolate 
was called as a “unique Gaza strain” with PVL toxin gene positive, while all the other 
isolates with the spa type t223 did not carry the PVL toxin gene (Al Laham et al., 2015). 
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In this present study, also, one isolate has shown a pattern as similar as the unique Gaza 
strain with spa type t223, SCCmec type IV, PVL positive and TSST-1 negative. 
 
Notably, in this study, the Gaza clone (t223) with TSST-1 positive, CC22 and SCCmec 
type IV was detected in the isolates collected from Al- Makassed Islamic Charitable 
Society Hospital only. Six isolates were from Gaza patient and five isolates were from 
patients living in Jerusalem and its suburbs. Interestingly, this could be explained due the 
transmission of the Gaza clone to other Palestinian populations as Gaza patients were 
referred to Al- Makassed Islamic Charitable Society Hospital in Jerusalem. 
 
Also, the spa type t223 was identified as the most dominant MRSA lineage among 
isolates from health care workers, adults and children in the community of the Jordanian 
population (Aqel et al., 2015). Moreover, the spa type t223 was also reported in other 
countries, such as: Kuwait, Egypt and Saudi Arabia (Abou Shady, Bakr, Hashad, & 
Alzohairy, 2015; Khairalla et al., 2017; Udo & Al-Sweih, 2017; Udo, Boswihi, & Al-
Sweih, 2016). This transmission of MRSA strains could be due to national travels 
between these countries. 
 
In our study, the spa type t008 was predominant in 12 MRSA isolates. Nine of them were 
related to the USA-300 clone, harboring both the PVL and the ACME-arcA toxin genes 
(8% of all isolates). This clone is the most widespread CA-MRSA clone in the United 
States and had emerged in the late 1990s. It is a common cause of SSTIs. Also, it is 
widely spread in Canada and Europe. This clone is a significant and dramatic epidemic 
clone due to its carriage of virulence and resistance determinants that may enhance 
severity and pathogenicity of the isolated strain (Alam et al., 2015; Diep et al., 2006).  
The carriage of PVL toxin gene among the CA-MRSA strains, especially the USA-300 
clone, is crucial and make these strains hyper-virulent and considered as a potential cause 
of increased CA-MRSA virulence which may cause occasionally fatal infections (Otto, 
2010). This pore-forming toxin induces polymorphonuclear cell death by apoptosis, 
increasing the pathogenicity of the MRSA isolates that are carrying this potent cytotoxin 
factor (Genestier et al., 2005; Loffler et al., 2010).  
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To the best of our knowledge, our study is the first study that has characterized the 
presence of the USA-300 clone in Palestinian regions. Whereas, we have detected this 
clone among nine t008 MRSA isolates, while this clone and the PVL toxin gene were not 
detected among the spa type t008/CC8 isolates in a study done on Palestinian Gaza 
patients (Al Laham et al., 2015). Also, the ACME-arc toxin gene presence was not 
characterized by Al-Laham et al, while it was found in 18.8% of MRSA isolates in our 
study. In contrast, the TSST-1 gene was highly harbored (27.4%) among MRSA isolates 
(Al Laham et al., 2015).  
 
The spa type t044, which is mostly PVL positive, was predominant in our study. A study 
was conducted in Middle East including Jordan and Lebanon has revealed the 
significance and the spread of this spa type in the Middle East with a high prevalence of 
both the PVL and TSST-1 (73% and 19%, respectively). This study was in agreement 
with our results regarding the genetic diversity of MRSA strains (Harastani & Tokajian, 
2014). They have explained that this could be due to genetic mutations and differences in 
the antibiotic descriptions between countries and this may led to the development of 
heterogeneous strains (Harastani & Tokajian, 2014). 
For the toxin genes profiling we found the PVL, TSST-1, and ACME-arcA toxin genes in 
29.5%, 23.2% and 18.8% of all isolates, respectively. While a similar study conducted in 
China has detected the PVL and TSST-1 toxin genes in 11, 3% and 18.8%, respectively 
(Wang et al., 2017). Another previous study conducted in Armenia has not detected the 
PVL toxin gene in any of MRSA isolates and detected the ACME-arcA in 15% of all 
MRSA isolates (Mkrtchyan et al., 2017). This indicates that there is a high carriage of 
PVL, ACME-arcA, TSST-1 and ETA these toxin genes among MRSA strains in 
Palestine. 
In summary, this phenotypic and genotypic diversity in the antimicrobial resistance rates 
and harboring several toxin genes by MRSA isolates in Palestine is crucial and may be 
contributed by the surge of more difficult MRSA infections which may be associated 
with more social and economic burdens. Thus, there is an urgent need to develop better 
measurements among clinical microbiology laboratories for proper detection and 
reporting of MRSA isolates and deep knowledge among physicians toward antibiotic 
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prescription practices. This may control and limit the development and spread of new 
clones and more complicated MRSA infections. 
 
5.2 Conclusion 
 
Our results provide important insights into the epidemiology of MRSA strains in 
Palestine with high carriage of different toxin. We report a diversity of MRSA strains in 
hospitals in Palestine, with frequent SCCmec type IV carriage. Knowledge of the 
dominant MRSA clones in our region with the antimicrobial susceptibility profile is 
necessary for selection of the appropriate empirical antimicrobial treatment of MRSA 
infections. 
 
5.3 Limitations and strengths: 
 
This study had limitations concerning the cooperation from hospitals regarding the 
provision of sample, whereas most of the samples were from Al-Makassed Islamic 
Charitable Society Hospital. Also, some of the demographic data were nor found or 
accessible for some isolates, especially the clear categorization of CA-MRSA or HA-
MRSA according to hospitalization days and exposure to health care facilities. 
 
This study has two strong points. First, the sample size (112 isolates) was relatively large 
regarding other cross sectional studies conducted in Palestine on MRSA carriage or 
molecular characterization (Essawi et al., 1998; Kaibni et al., 2009; Sabri, Adwan, 
Essawi, & Farraj, 2013). The second point is the relatively deep and diverse analysis of 
the molecular profile and the toxin genes for each isolate. To the best of our knowledge, 
this study is the first study that analyze the antibiograms, the SCCmec type, the spa type 
(107 isolates were sequenced by spa typing) and four associated toxin genes related to 
MRSA.  
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5.4 Recommendations 
Due to the shift of MRSA infections to the community and the high carriage among 
populations, no individual or group can be considered not at risk for CA-MRSA 
infection. This worthy point needs further attention because interesting and meaningful 
results and control programs can be achieved. Control measures are needed to minimize 
and control the spread of the MRSA in general and the dramatic clones specifically, such 
as the (USA-300) found throughout this study. 
Regarding the appropriate treatment approaches, culturing is recommended for the 
MRSA infections because it is the only ideal predictor of the appropriate antibiotics 
therapy. Also, the appropriate empirical antibiotic therapy is essential for saving patients 
and reducing the mortality rates in the complicated hospitalized patients. Thus, 
educational and awareness programs are recommended for both the physicians and the 
medical laboratories for reliable appropriate diagnosis and proper antibiotic therapy 
decisions. This can help to minimize the development for more complicated resistant 
MRSA strains in hospitals and may save many immunocompromized hospitalized 
patients. 
All together, these points suggest the need for efficient future surveillance studies and 
infection control strategies. Also, more spa typing and sequencing based studies are 
needed to associate the antimicrobial resistance patterns with the spa types and their 
corresponding CCs. 
5.5 Future plan:  
We are planning to do the MLST for some of representative isolates with the unique or 
rare strains and compare it with the CCs we were able to conclude through the algorithm 
BURP. Also, to concern on the spa or the SCCmec non-typeable isolates we found 
throughout our research and to identify the sub-types of SCCmec IV since it was the most 
dominant type in this study. Currently, among this study SCCmec type IV isolates, the 
most common SCCmec subtype was found to be mostly SCCmec subtype IVa. However, 
this SCCmec sub-typing is still under testing and investigations. 
87 
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Chapter Seven:  
 
Appendices 
 
Table 1: Bacterial Culture Media and freezing solutions 
# Item Manufacture 
1 Blood Agar Base (Infusion Agar) HIMEDIA (India) 
2 Muller Hinton Agar HIMEDIA (India) 
3 Coagulase Mannitol Salt Agar Base HIMEDIA (India) 
4 Brain Heart Infusion Broth HIMEDIA (India) 
5 Pure Glycerol EMPROVE (Germany) 
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Table 2:  Materials and reagents used in this study 
# Reagent Manufacture 
1 Antibiotic Disks Oxoid (UK) 
2 Gram Stain Kit SIGMA 
3 DNA Molecular weight marker (1Kb/ 
100 bp ladders) 
ThermoScientific, (USA) 
4 DNA extraction kit Nucleospin, Macherey-Nagel, (Germany) 
5 lysostaphin 1 mg/mL PROSPEC 
6 lysosyme 1mg/mL PROSPEC 
7 Primers Hylabs, Israel 
8 PCR-Ready Products Syntezza, Israel 
9 PCR Master Mix ThermoScientific, (USA) 
10 PCR tubes 4titude, EU 
11 Ultra-Pure Water Fisher 
12 Freezing tubes Nunc Cryotube Vials, Denmark 
13 Etidium Bromide AMRESCO 
14 Agarose Gel SeaKem® LE agarose gel 
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Table 3: Apparatus and special equipments used in this study 
# Item Manufacture 
1 Autoclave __ 
2 Petri Dishes Miniplast/ Ein-Shermer 
3 Hot plate Stuart 
4 Sensitive Balance Sartorius 
5 Research pipettes Eppendrof 
6 Nanodrop 1000 spectrophotometer ThermoScientific 
7 Thermal cycler Biometra TProfessional Basic  Gradient  
Thermocycler 
8 Microwave oven LG 
9 Electrophoresis set-up Bio-Rad 
10 Electrophoresis Power supplier Consort 
11 Spectrafuge Labnet 
12 UV light Bio-Imaging Systems MiniLumi 
transilluminator 
 
 
- TAE buffer preparation: 
 
The pre-diluted 1x TAE buffer was prepared by suspending 20 ml from 50x concentrated 
buffer to 1000 mL dd H2O. The 50x concentrated TAE buffer was prepared by dissolving 
242 gm Tris base and 57.1 gm acetic acid  in 100 ml 0.5M EDTA with dd H2O to 1L. 
Mixture was shaked vigorously and PH was adjusted to 8.5 using KOH. 
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Table 4: Antimicrobial resistance rates (%) and MDR isolates associated with the spa 
types and CCs found using BURP among 112  
studied MRSA isolates. 
 
Data are represented in percentage (%) of the resistance rates for each of the following antibiotics: FOX: 
Cefoxitin, Pen G: Penicillin G, AMC: Amoxicillin/Clavulanic acid, CRO: Ceftriaxone, MEM: Meropenem, 
E: Erythromycin, C: Clindamycin, CIP: Ciprofloxacin, CN: Gentamicin, SXT: Trimethoprim-
sulfamethoxazole, V: Vancomycin. The 32 MDR isolates were distributed among 16 spa types, the spa (*) 
isolate and 2 spa (err) isolates (red line). The last column (red) indicates the total percentage of the 
antimicrobial resistance rate for each antibiotic distributed among different spa types, while the last line 
indicates the total number of isolates tested within each spa type and CCs found in this study. 
 
 
   t008 t011 t018 t021 t037 t044 t084 t085 t104 
t109
4 t121 
t124
7 t127 t131 
t151
6 t223 t304 t314 t318 t359 t386 t541 t605 t648 t688 t932 t991    
   8 NF 30 30 
8/23
9 80 15 NF 5 NF 8 NF 1 80 22 22 6 121 30 8 1 22 126 8 5 NF 913     
   10.7 0.89 0.89 6.30 8.9 10.7 0.89 0.89 1.8 0.89 0.89 0.89 0.89 2.7 3.6 9.8 2.7 0.89 0.89 0.89 12.5 0.89 0.89 0.89 2.7 0.89 5.4    
    10.7 0.9 0.9 6.3 8.9 10.7 0.89 0.89 1.8 0.89 0.89 0.89 0.89 2.7 3.6 9.8 2.7 0.89 0.89 0.89 12.5 0.89 0.89 0.89 2.7 0.89 5.4    
   10.7 0.9 0.9 6.3 8.9 10.7 0.89 0.89 1.8 0.89 0.89 0.89 0.89 2.7 3.6 9.8 2.7 0.89 0.89 0.89 12.5 0.89 0.89 0.89 2.7 0.89 5.4    
   10.7 0.9 0.9 6.3 8.9 10.7 0.89 0.89 1.8 0.89 0.89 0.89 0.89 2.7 3.6 9.8 2.7 0.89 0.89 0.89 12.5 0.89 0.89 0.89 2.7 0.89 5.4    
   10.7 0.9 0.9 6.3 8.9 10.7 0.89 0.89 1.8 0.89 0.89 0.89 0.89 2.7 3.6 9.8 2.7 0.89 0.89 0.89 12.5 0.89 0.89 0.89 2.7 0.89 5.4    
   8.9 0.0 0.0 5.4 3.6 5.4 0.89 0.0 1.8 0.0 0.89 0.89 0.89 2.7 2.7 4.5 0.0 0.0 0.89 0.89 12.5 0.89 0.0 0.89 0.9 0.89 1.8    
   4.5 0.0 0.0 2.7 1.8 3.6 0.0 0.0 0.0 0.0 0.0 0.89 0.0 1.8 1.8 1.8 0.0 0.0 0.89 0.89 7.1 0.0 0.0 0.89 0.89 0.89 0.0    
   8.0 0.89 0.0 0.0 7.1 4.4 0.0 0.0 0.0 0.89 0.89 0.0 0.89 0.89 0.89 0.89 0.0 0.0 0.89 0.89 2.7 0.0 0.0 0.0 0.89 0.89 0.89    
   0.0 0.0 0.89 0.0 7.1 1.8 0.0 0.0 0.0 0.89 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.89 2.7 0.89 0.0 0.0 0.0 0.89 1.8    
   0.89 0.89 0.00 0.89 0.89 1.80 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 2.7 0.0 0.0 0.0 0.0 0.0 0.89 0.89 0.89 1.8 0.0 0.89    
   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0    
   4 0 0 1 3 4 0 0 0 0 0 0 0 0 3 2 0 0 1 1 2 1 0 1 1 1 1    
 
   12 1 1 7 10 12 1 1 2 1 1 1 1 3 4 11 3 1 1 1 14 1 1 1 3 1 6    
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